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GENERAL INTRODUCTION AND THESIS OUTLINE 
Ovarian cancer is the fifth most frequent cancer in females. 70% of the patients with ovarian 
cancer have advanced stage disease at the time of diagnosis as the spread of the cancer cells 
through the abdominal cavity occurs early in the development of the disease. Advanced stage 
ovarian cancer is characterized by metastatic deposits on the peritoneum called peritoneal 
carcinomatosis (PC). PC is responsible for a low quality of life and a high morbidity and 
mortality. Improvements in systemic chemotherapy have not resulted in a long-term survival. 
In the 1990s intraoperative intraperitoneal chemotherapy (IPEC) following a complete 
cytoreductive surgery (CRS) was developed for the treatment of PC replacing standard 
intravenous (IV) therapy.  
IPEC has pharmacological and clinical advantages over IV chemotherapy in women with 
optimally debulked epithelial ovarian cancer. This alternative therapy is showing promising 
results with an increased 5-year survival of 44% compared to 30% after traditional IV 
treatment. The rationale for IP therapy is based on the presence of the peritoneal-plasma 
barrier which allows the use of higher cytotoxic doses in combination with a reduced systemic 
toxicity. 
Although IPEC therapy has already been used for more than a decade, a lot of uncertainties 
still exist in terms of therapeutic schedule, used temperature, residence time, drug, or carrier 
solution.  
In this study, paclitaxel (PTX) is used as chemotherapeutic agent as PTX has an appropriate 
pharmacokinetic profile for IP use. Due to its high molecular weight it has a limited absorption 
through the peritoneal-plasma barrier and when systemically absorbed its hepatic metabolism 
decreases the systemic side effects. Although PTX is a very promising molecule for IP 
treatment, it is not often used as allergic reactions are often observed due to the presence of 
Cremophor®EL, the vehicle of PTX in the commercially available formulation, Taxol®. Due to 
these toxicity issues a lot of research is performed to develop new PTX formulations in order 
to minimize the side effects. But all these developed formulations are not specifically 
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approved for IP therapy, and current IP chemotherapy in patients relies on the off-label use 
of products developed for IV applications.  
Thesis outline 
The Introduction provides a general overview of ovarian cancer, the development of 
peritoneal carcinomatosis and the main problems concerning the IPEC procedure. Moreover, 
in this introduction an overview can be found of different drug delivery systems developed for 
IP therapy. 
In Chapter 1 a new nanocrystalline PTX formulation with a high PTX-to-stabilizer ratio using 
the wet milling technique was developed which was suitable for IPEC treatment. In the same 
context, Chapter 2 describes the evaluation of the new, commercially available PTX 
formulations, Abraxane® and Genexol®PM, which were compared with Taxol® to evaluate 
their suitability for IPEC treatment. For all formulations the toxicity was evaluated by 
determining the maximum tolerated dose (MTD), recovery time and bioavailability and the 
efficacy was evaluated by a tumor growth delay study (TGD) and by analysing the PTX tumor 
concentration. The toxicity and efficacy were evaluated in a xenograft rat model with 
peritoneal carcinomatosis of ovarian origin. 
In most institutions hyperthermia is a standard component of the IPEC procedure although it 
remains unclear if the use of hyperthermia results in an beneficial effect. Therefore, in 
Chapter 2 the additional effect of hyperthermia was evaluated both in vitro and in vivo in 
combination with the different PTX formulations. 
As the limited drug penetration into tumor tissue is one of the major factors causing treatment 
failure, Chapter 3 evaluates the PTX tumor penetration profile after IPEC treatment. On the 
basis of these results, the pharmacokinetic parameters such as the contact time and the PTX 
dose were evaluated. 
Finally, in Chapter 4, a clinical study was performed in patients with peritoneal carcinomatosis 
of different origin. All patients underwent a cytoreductive surgery followed by an IPEC 
treatment with oxaliplatin, a frequently used chemotherapeutic agent. Patients were divided 
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in 3 treatment groups in order to evaluate the dose, the treatment time and the influence of 
hyperthermia on the efficacy and toxicity of the IPEC treatment. 
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HIPEC AS TREATMENT FOR PERITONEAL 
CARCINOMATOSIS OF OVARIAN ORIGIN 
 
 
 
 
Parts of this chapter are published in: 
L. De Smet, W. Ceelen, J.P. Remon, C. Vervaet, Optimization of Drug Delivery Systems for 
Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent, The 
Scientific World Journal, (2013), Article ID 720858, 7 pages, 
http://dx.doi.org/10.1155/2013/720858. 
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INTRODUCTION 
With more than 40 000 new cases every year in Europe, ovarian cancer is the second most 
common gynecological malignancy [1] and it is responsible for 5% of all cancer deaths in 
women [2]. The stage of the disease at the time of initial diagnosis is an important determinant 
of ovarian cancer survival. Ovarian cancer is known as a silent killer, as the symptoms of 
ovarian cancer are vague such as abdominal pain, bleeding and abdominal swelling, so 70% of 
the patients have advanced stage disease (stage III or IV) at the time of diagnosis [3].  
The different stages (Fig. 1) are characterized by: 
- Stage I: The cancer is still contained within the ovary (or ovaries). The cancer has not 
spread outside the ovary. 
- Stage II: The cancer is in one or both ovaries and has spread to other organs (such as 
the uterus, fallopian tubes, bladder, the sigmoid colon, or the rectum) within the 
pelvis. The cancer has not spread to lymph nodes, the lining of the abdomen (the 
peritoneum), or distant sites. 
- Stage III: The cancer is in one or both ovaries, and the cancer has spread beyond the 
pelvis to the peritoneum and/or to the lymph nodes. 
- Stage IV: This is the most advanced stage of ovarian cancer. In this stage the cancer 
has spread to the inside of the liver, the lungs, or other organs located outside the 
peritoneal cavity.  
In the 1960s, the 5-year relative overall survival for ovarian cancer was 30%. Improvement of 
the quality of the cytoreductive surgery (CRS) as well as development of novel drugs and new 
chemotherapeutic regimens have increased this 5-year relative overall survival to 44%, with 
the rates being 92%, 72%, 27% and 21% for stage I to IV, respectively (SEER-website, 2013) 
[3].  
Despite the advances made in cytotoxic therapy, the 5-year relative overall survival for 
patients with advanced stage disease remains low so it is important to understand the 
development of peritoneal carcinomatosis in order to respond better to the evolution of the 
cancer. 
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Figure 1. The FIGO classification (named after its authors, the International Federation of 
Gynaecological Oncologists) of the different stages of ovarian cancer. 
PHYSIOPATHOLOGY OF PERITONEAL CARCINOMATOSIS 
At the early stage of ovarian cancer the tumor is limited to one or both ovaries. The most 
common type of ovarian cancer, serous ovarian cancer, arises directly from the cells of the 
ovarian surface epithelium [4]. As a consequence of tumor growth, the capsule becomes 
disrupted and the tumor spreads beyond the confines of the ovaries by direct extension and 
invasion of adjacent organs such as the uterus, the mesothelial lining and the peritoneum [5]. 
Some malignant cells will detach from the original tumor. These exfoliated malignant tumor 
cells can be transported throughout the abdominal cavity by the peritoneal fluid before 
seeding intraperitoneally (Fig. 2).  
Diaphragmatic respiratory movements and intestinal peristalsis result in hydrostatic pressure 
differences between the lower and upper abdomen which are capable of conveying peritoneal 
fluid from the pelvis to the subhepatic and subphrenic regions, even in the upright position. 
This transport can affect multiple vital organs within the abdomen, including the 
gastrointestinal systems. Nests of tumor cells are commonly observed on the omentum, the 
mesentery and the diaphragm [6].  
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This seeding is also associated with the formation of malignant ascites, resulting in raised 
intra-abdominal pressure, abdominal distention and discomfort. In contrast to most other 
cancer types, dissemination through the vasculature is rare [7]. However in advanced stage 
disease, there is a high incidence of pelvic and paraaortic lymph node involvement [8, 9].  
 
Figure 2. The mechanism of peritoneal dissemination from ovarian origin (adapted from [7]). 
TREATMENT OF ADVANCED OVARIAN CANCER 
Peritoneal carcinomatosis (PC) is associated with gastrointestinal symptoms and impaired 
quality of life (QOL), and is often a marker of poor prognosis. In the final stages of PC, patients 
suffer from severe anorexia, dyspnea and pain from malignant bowel obstruction, ascites and 
pleural effusion as a result of extensive tumor burden [10]. PC of ovarian origin was 
traditionally regarded as a terminal condition. The terminal nature of this disease has been 
demonstrated in a large clinical trial, the French EVOCAPE I trial, which prospectively followed 
patients with PC of different primary cancers from diagnosis till death. The overall survival for 
patients with PC of ovarian origin was 12 to 23 months [11].  
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In the early 1990s, adjuvant intravenous (IV) chemotherapy with cisplatin or carboplatin in 
combination with cyclophosphamide was the standard of care for the treatment of advanced 
ovarian cancer. Since the mid-90s cytoreductive surgery (CRS) followed by a combination IV 
therapy with a platinum compound and a taxane became the first line treatment [12, 13]. 
Despite this progress in systemic chemotherapy, most patients relapsed and ultimately died 
from their disease. The addition of intraperitoneal (IP) chemotherapy for the treatment of 
advanced ovarian cancer has been showing promising results. 
Since the 1980s, different treatment options for patients with isolated PC were proposed 
based on the hypothesis that PC is a locoregional disease which would benefit from a local 
therapeutic approach [14]. The rationale of using local IP therapy for the treatment of PC is 
based on the pharmacokinetic advantages, such as high local concentration with a longer half-
life of the drug in the peritoneal cavity, which improves the interaction of the cytotoxic agents 
with the cancer cells. 
INTRAPERITONEAL CHEMOTHERAPY 
The current treatment protocols for peritoneal carcinomatosis are based on a combination of 
cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy. 
The aim of CRS is to eliminate all macroscopic disease. At the beginning of the surgical 
procedure, most surgeons quantify the extent of the peritoneal carcinomatosis by the 
Peritoneal Cancer Index (PCI) [15]. The PCI gives valuable information about the exact 
distribution of seeding and tumor volume, representing in detail the extent of the peritoneal 
spread. The PCI is an assessment that combines lesion sizes (0 – 5 cm) with tumor distribution 
(abdominal-pelvic regions 0 – 12). The extent of the disease is quantified as a numerical score 
(fig. 3). The PCI score has been found to be an prognostic indicator of survival. 
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Figure 3. The peritoneal cancer index. 
After CRS the residual tumor nodules are also quantified and scored as the size of the residual 
tumor nodules is the major prognostic indicator for the outcome of the disease. The definition 
of complete CRS is no visible evidence of cancer (CC-0) or only small residual nodules with a 
size less than 2.5 mm (CC-1), since this ensures sufficient drug penetration into the tumor 
during subsequent intraperitoneal chemotherapy. CRS with residual tumors with a diameter 
>2.5 mm (CC-2 and CC-3) is considered to be incomplete and these patients have a low survival 
rate [16, 17].  
A second essential part of the current management of PC is the perioperative intraperitoneal 
chemotherapy which targets the residual microscopic disease. IP treatment of patients with 
PC was first reported by Spratt et al., who used triethylenethiophosphoramide in a patient 
with pseudomyxoma peritonei (PMP) [14] and by Speyer & Myers, who administered 5-
Fluorouracil (5-FU) and methotextrate intraperitoneally under normothermic conditions to 16 
patients with PC [18]. In 1988, Koga et al. reported intraperitoneal chemotherapy in 23 
patients with PC from gastric cancer origin [19]. 
The adjuvant perioperative intraperitoneal chemotherapy can be applied directly after CRS 
under normothermic or hyperthermic conditions (i.e. (hyperthermic) intraperitoneal 
chemotherapy or (H)IPEC) as a part of the surgical procedure, or can be started the first 
postoperative day and continued for several (usually five) days (i.e. early postoperative 
intraperitoneal chemotherapy or EPIC). No randomized trials have been published comparing 
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the survival outcomes between EPIC and HIPEC [20]. EPIC has been associated with a higher 
risk of complications after CRS, possibly due to the prolonged contact between the 
chemotherapeutic agent and damaged tissues at the operated surfaces [21]. Other 
disadvantages of EPIC are an uneven distribution of the chemotherapeutic fluid in the 
abdomen and less comfort for the patients (e.g. nausea and impaired mobility) linked to the 
chemotherapeutic fluid present in the abdomen [22]. As the main drawback of (H)IPEC is the 
necessity to perform this technique in the operating room, requiring specialized equipment 
and an experienced perfusionist, (H)IPEC is the preferred technique.  
PHARMACOKINETIC RATIONALE BEHIND IP THERAPY 
The rationale behind the IP administration of chemotherapy is based on the presence of a 
peritoneal-plasma barrier [23]. The peritoneum consists of 2 parts which line the peritoneal 
cavity, the visceral peritoneum covers the intra-abdominal organs and mesenteries while the 
parietal peritoneum lines the abdominal wall, the pelvis, the anterior surfaces of the 
retroperitoneal organs and the inferior surface of the diaphragm. The total area of the 
peritoneum can be compared to the skin area. 
The peritoneum barrier is a complex, three-dimensional structure made up of (a) the 
peritoneum, a monolayer of mesothelial cells supported by a basement membrane, (b) five 
layers of connective tissue which include interstitial cells, a collagen matrix, hyaluronan and 
proteoglycans and (c) the cellular component which consists of fibroblasts, pericytes, 
parenchymal cells and blood capillaries. Contrary to intuition, it is not the mesothelial lining 
which is the main transport barrier but the capillary walls and the surrounding interstitium 
which are the most important barriers for the transport from the abdominal cavity to the 
plasma [24]. 
In general there are 3 exits from the peritoneal cavity: (1) diffusion through the parietal 
peritoneal surfaces, (2) diffusion through visceral peritoneal surfaces, and (3) absorption 
through lymphatics. 
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The rate at which a drug leaves the peritoneal cavity and enters the plasma is the critical 
mechanism by which peritoneal drug concentrations fall following IP administration. 
The transport through the peritoneum was described by a simplified mathematical formula, 
where both plasma and the peritoneal cavity are considered as a single compartment 
separated from each other by an effective membrane [25]. 
Rate mass transfer = PA (Cp – CB) 
With PA the permeability area (effective contact area x permeability), Cp the concentration in 
the abdominal cavity and CB the concentration in the blood. This formula indicates the 
importance of the size of the effective contact area of the peritoneal membrane. 
 
Figure 4. Traditional two-compartment model of peritoneal transport in which transport of a drug from 
the peritoneal cavity to the blood occurs across the peritoneal membrane. 
This model (Fig. 4) indicates that large molecular weight substances such as many 
chemotherapeutic agents would be cleared more slowly from the peritoneal cavity than from 
the systemic circulation. This would increase drug exposure to the tumor-containing area. The 
pharmacokinetic rationale of (H)IPEC is based on the dose intensification provided by the 
administration of chemotherapy into the peritoneal cavity and the delayed clearance caused 
by the peritoneal plasma barrier. The peritoneal clearance is inversely proportional to the 
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square root of the molecular weight of the drug which results in a higher concentration in the 
peritoneal cavity than in the plasma after intraperitoneal administration [26]. 
This model suggests furthermore high local drug concentrations which are in contact with the 
tumor-affected region but this leads not automatically to high tumor concentrations. This 
model does not reveal anything about the specific tumor penetration. A high concentration 
gradient as driving force may lead to an increased diffusion into the tumor. Many studies have 
shown only a limited tissue and tumor penetration of the chemotherapeutic agents. This 
limited penetration may limit antitumor effect, but it also may protect sensitive normal cells 
on the mucosal side of the gastrointestinal tract.  
POINTS TO CONSIDER ABOUT (H)IPEC 
It has been found that IP therapy and in particular (H)IPEC is a promising therapy for PC 
treatment. Although IP therapy is already conducted for many years in different clinical 
institutions, no standard treatment in terms of schedule, residence time, drug, or carrier 
solution has been established. Parameters such as open or closed technique, 
chemotherapeutic agent, temperature, perfusate volume and duration of the perfusion differ 
from institution to institution. Hereafter issues as the technique, the use of the cytostatic drug, 
the available pharmaceutical formulations and the used temperatures are discussed. 
1.  (H)IPEC, the technique 
(H)IPEC can be performed by the open, the partially closed and the closed technique. Whether 
an open or (partially) closed technique is used, is based on the surgeon’s preference [27]. 
When performing the open (H)IPEC technique, the procedure is carried out before closing the 
abdominal cavity. The open abdomen is covered with a plastic sheet, to create a “Coliseum” 
container (Fig. 5). The plastic sheet is opened in the midline to allow the surgeon to manipulate 
the viscera and a smoke evacuator is placed to clear aerosolized chemotherapy. By 
manipulation, the surgeon is causing a homogenous distribution of the chemotherapeutic 
agent in the abdominal cavity. Cancer cells from surfaces that would otherwise not be 
accessible are therefore reached [15].  
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Figure 5. Hyperthermic intraperitoneal chemotherapy administered using the open technique. 
Environmental safety aspects are an argument for the use of the closed (H)IPEC technique. 
During this procedure the abdomen is closed before administration of the chemotherapy. 
There are two variations of closed techniques. In the first one, only the skin is closed. After 
(H)IPEC the abdomen is reopened, and the surgeon will perform the anastomoses. This 
technique is called the partially closed technique. For the closed technique, the anastomoses 
were performed before closing the abdominal cavity and administration of the chemotherapy. 
Studies already have proven that thermal homogeneity and a homogenous distribution of the 
chemotherapy were less obtained during the closed techniques [28]. 
2. Drug selection for IP chemotherapy 
In the case of IP therapy, the cytotoxic agent must be able to penetrate the peritoneal surface 
and the tumor nodules effectively, in combination with its ability to eradicate microscopic 
residual disease within the peritoneal fluid. During IP therapy, drug delivery to peritoneal 
tumors is twofold. The primary route is drug diffusion through the tumor interstitium, while 
the second route is the recirculation of the drug absorbed from the peritoneal cavity (Fig. 6). 
However, it is evident that the latter route is of minor importance as efficient and safe IP 
therapy requires systemic drug levels as low as possible in order to minimize systemic side 
effects caused by the cytotoxic agent. 
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Figure 6. Chemotherapeutics enter the tumor through direct surface contact and by crossing the 
peritoneal-plasma barrier and entering the tumor microcirculation. 
One of the major challenges of IP therapy is to maintain a high local drug concentration within 
the peritoneal cavity to provide a sufficient concentration gradient as driving force for drug 
diffusion into the tumor. The residence time of small molecular weight drugs in the peritoneal 
cavity may not be sufficient because they are quickly absorbed through the peritoneal 
capillaries into the systemic circulation [29]. Therefore, the drug delivery system used for IP 
therapy is an important factor to deliver drugs efficiently to the target tissue. In addition, 
different parameters must be considered to select the ideal chemotherapeutic agent for IP 
therapy and to maximize its efficacy: cavity-to-plasma AUC ratio, systemic absorption, depth 
of tumor penetration, intrinsic activity of the agent against the primary tumor type [30].  
In general, water insoluble molecules with a high molecular weight and a high peritoneal-to-
plasma AUC ratio remain longer in the peritoneal cavity and are thus preferred for IP 
treatment (Table I) [23, 31]. One important consideration is that a high peritoneal-to-plasma 
AUC ratio does not automatically confer a higher efficacy, since the penetration of the 
chemotherapeutic agent into the tumor might be limited. 
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Table I. Water solubility, the partition coefficient (log P) and peritoneal-to-plasma drug area 
under the curve (AUC) ratio of intraperitoneal chemotherapeutic agents. 
Chemotherapeutic agent Molecular weight Water solubility Log P 
Peritoneal-to-
plasma AUC ratio 
Cisplatin 300 Good -2.19 12 
Carboplatin 371 Good 1.06 10 – 18 
Oxaliplatin 397 Good 1.73 16 
Paclitaxel 854 Poor 3.54 1000 
Docetaxel 862 Poor 2.92 181 
5-Fluorouracil 130 Sparingly -0.89 367 
Doxorubicin 544 Poor 1.27 474 
 
The ideal drug for IP therapy has a high penetration into the tumor nodule. This high 
penetration in combination with a slow diffusion of the chemotherapeutic solution through 
the capillary endothelium results in low systemic concentrations and a reduced systemic 
toxicity by rapid metabolism of the drug. 
Paclitaxel 
In the early 1960s, the cytostatic effect of the Taxus Brevifolia was shown through a program 
of the National Cancer Institute (USA). 10 years later in 1971, the active compound paclitaxel 
was isolated and characterized, and another 10 years later the method of action was 
discovered [32, 33]. They found that PTX binds to the microtubule rather than to the tubulin 
dimers, both essential for mitosis, maintenance of cell shape, intracellular transport, cell 
signaling and division. The β-tubulin in the microtubule is the cellular target for PTX. PTX forms 
very stable and dysfunctional microtubules and is thus known as a microtubule-stabilizing 
agent. Hereby, PTX blocks the normal microtubule dynamics during mitosis. This causes that 
the cell goes into a mitotic arrest followed by apoptosis and necrosis [34].  
The use of PTX for IP treatment of PC of ovarian origin is rational, because of its high activity 
against ovarian cancer cells and expected favorable pharmacokinetics because of its limited 
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absorption from the peritoneal cavity due to its high molecular weight (853.9), low water 
solubility (20 µg/ml) and significant first pass effect.  
Different studies demonstrated a significant pharmacokinetic advantage of PTX for IP therapy. 
The first study of PTX IP therapy was published by Markman et al. (1994) [35]. The AUC after 
IP treatment was 1000-fold higher compared to the plasma AUC, and persisted for more than 
24 – 48 hours after a single dose. Other studies [36] showed significant peritoneal 
concentrations till one week after IP administration. PTX proved already its excellent activity 
against ovarian cancer since the 1990s, with a low toxicity and good tolerance in peritoneal 
administration. Experimental studies have demonstrated that even short-time exposure of 
tumor cells to high concentrations of PTX, as during HIPEC, are extremely sufficient to induce 
extended cell growth arrest and cell death by necrosis and apoptosis [37, 38]. 
 
Figure 7. Chemical structure of paclitaxel. 
Although PTX is a very promising molecule for IP therapy, it is not often used in clinical practice 
as it causes various side effects, as serious dose-limiting toxicities such as myelosuppression, 
peripheral sensory neuropathy and allergic reactions. In 40% of the patients hypersensitivity 
reactions are observed and 3% of the patients have potentially life-threatening side effects. 
These side effects have been associated with Cremophor®EL, present in the first commercially 
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available formulation Taxol® (i.e. paclitaxel dissolved in a 50/50 (v/v) mixture of ethanol and 
Cremophor®EL). In recent years a lot of research was performed to develop new PTX 
formulations on the one hand and on the other side to discover novel second-generation 
taxanes both with the goal to increase the selectivity and efficacy, and to reduce the systemic 
toxicity. Table II gives an overview of the new taxane analogs (Table IIa) and new PTX 
formulations (Table IIb) which are FDA-approved or in the final stage of clinical development 
for the treatment of various solid tumor malignancies [39]. 
Table IIa: New second-generation taxanes. 
Analogues Potential indications 
Cabazitaxel 
Prostate [40] 
Breast [41] 
Tesetaxel 
Breast [42] 
Non-small-cell lung carcinoma [43] 
Gastroesophageal [44] 
Melanoma 
Larotaxel 
Non-small-cell lung carcinoma [45] 
Breast [46] 
 
All these formulations are very promising but are developed for IV treatment. Today there are 
no chemotherapeutic formulations specifically approved for IP therapy, and current IP 
chemotherapy in patients relies on the off-label use of products developed for IV applications.  
These formulations designed for IV therapy often suffer from a rapid clearance from the 
peritoneal cavity, fast absorption through the lymphatics, no tumor selectivity and local and 
systemic toxicity caused by the high blood concentrations after systemic absorption. These 
issues, which reduce the efficacy of IP therapy, dramatically limit the use of conventional IV 
chemotherapeutic formulations for IP use [47]. Inadequate drug delivery to solid tumors is a 
major cause of IP treatment failure. As a result, a number of drug delivery strategies (which 
are reviewed in the remainder of this Introduction) have been investigated to extend the 
residence time of the chemotherapeutic agent and to optimize IP therapy (Table III). 
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Table IIb. New paclitaxel formulations. 
Name Composition Potential indications 
Abraxane® Albumin-bound nanoparticles of PTX 
Breast [48] 
Ovarian [49] 
NSCLC [50] 
Ovarian [53] 
Pancreas [51] 
Opaxio® 
Polyglumex-CT2103 
Prodrug 
Water-soluble polymer of glutaric acid 
linked to PTX 
NSCLC [52] 
Ovarian [53] 
Glioblastoma 
Esophageal [54] 
Genexol®PM 
Polymeric-micellar (biodegradable block 
copolymer which includes 
monomethoxy poly(ethylene glycol)-
block-poly(D,L lactide)) 
NSCLC [55] 
Breast [56] 
Gastric [57] 
Taxoprexin® 
Docosahexaenoic acid (DHA)-PTX 
Prodrug 
NSCLC [58] 
Melanoma 
 
 
Oxaliplatin 
The successful treatment of a variety of cancers with metal-containing anti-cancer drugs 
started with cisplatin [59]. Although the compound was already described in 1845, its anti-
cancer activity was only discovered in 1964 [60]. Due to the side effects of cisplatin, a second 
generation platinum-containing agent, carboplatin, was developed, and over the past 30 years 
these compounds have dominated the anticancer treatments. In addition to the side effects, 
the use of (cis)platinum was also hampered by the fact that certain tumors developed 
resistance against it. Hence intensive research programmes were initiated to develop less 
toxic and resistance-free platinum complexes [61]. As a result more than 3000 platinum 
analogues were synthetized over the past 30 years. However, only 12 reached clinical trials 
and currently just 3 platinum-compounds are registered on the European market (cisplatin, 
carboplatin and oxaliplatin).  
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Oxaliplatin (oxalate (trans l-1,2-diaminocyclohexane)platinum)) (Fig. 8), a third generation 
platinum-containing agent, is developed to improve the toxicological profiles and overcome 
the platinum-resistance in solid tumors. In an oxaliplatin molecule, both amino groups of 
cisplatin are replaced by a diaminocyclohexane group (DACH) while an oxalate group is added 
as leaving group to improve the solubility. These groups play an important role in the cytotoxic 
effect of oxaliplatin [62, 63]. 
The method of action of oxaliplatin starts with a non-enzymatic transformation by the 
displacement of the oxalate group which appears responsible for the formation of its ultimate 
cytotoxic form. The inert DACH-complex enters the cell and causes DNA damage. Apoptosis of 
cancer cells can be caused by formation of DNA lesions, arrest of DNA synthesis, inhibition of 
RNA synthesis, and triggering of immunologic reactions [63, 64]. Oxaliplatin also has a 
synergestic effect in combination with 5-FU but the underlying method of action is not well 
understood [65]. 
 
Figure 8. Chemical structure of oxaliplatin. 
Oxaliplatin was already discovered in 1976  but was only introduced in clinical trials in 1985 
[66]. It was used for the first time for the treatment of advanced colon cancer in the mid-90s 
in combination with 5-FU. Oxaliplatin (Eloxatin®) was EMA approved (France) in 1996 and FDA 
approved in 2002 for the treatment of advanced and metastatic colon cancer in combination 
with 5-FU but it is active against a variety of cancers including ovarian and gastric cancer and 
malignant mesothelioma [67-69]. 
Oxaliplatin has provided significant response rates alone or in combination with 5-FU and 
leucovorin for the treatment of advanced stage colon cancer [63]. After intravenous 
oxaliplatin administration, the penetrated concentration into the tumor tissue is not sufficient 
to eliminate the disease effectively. For PC, experimental studies have shown that 
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intraperitoneal oxaliplatin treatment improved the exposure of oxaliplatin to the peritoneal 
surfaces compared to intravenous therapy [70]. The choice for oxaliplatin for IPEC treatment 
is rational as it has favourable pharmacokinetic and pharmacodynamic properties [71]. Elias 
et al. has shown that IPEC treatment with oxaliplatin in combination with intravenous 5-FU 
improved the overall survival [72] without increasing the systemic toxicity [73]. For ovarian 
cancer, IPEC with oxaliplatin is mainly used for patients showing resistance against cisplatin or 
hypersensitivity reactions [74].  
3. Drug delivery systems for IP therapy 
Microspheres 
Microspheres (>1 µm) can be designed to release the drug gradually over time using a wide 
variety of biodegradable and biocompatible polymeric substances. The size of the 
microspheres is the most important factor that influences residence time in the peritoneum, 
since microspheres smaller than 8 µm may disappear from the peritoneal cavity through the 
lymphatic capillaries [75].  
Microspheres for IP drug delivery are often based on biodegradable aliphatic polyesters of 
hydroxyl acids such as poly(lactic-co-glycolic)acid (PLGA) and related polymers. PLGA was for 
example used to incorporate cisplatin (cis-dichlorodiammmine-platinum(II)) in microspheres. 
Cisplatin is a hydrophilic molecule which is, in solution, rapidly absorbed from the peritoneal 
cavity by the capillaries and transferred to the systemic circulation. Therefore biodegradable 
anti-cancer drug-loaded microspheres were developed which showed a long retention and 
sustained release of the drug. Cisplatin was released from the PLGA matrix by diffusion until 
14 days after IP administration. During this period the particles were retained in the abdominal 
cavity for a long period and gradually absorbed, which reduced the systemic side effects [76]. 
Another drug delivery system using PLGA is paclitaxel-loaded microparticles [77]. This system 
consists of two types of paclitaxel-loaded microparticles with different drug release rates 
obtained by the lactide/glycolide (L/G) ratio. First, a burst release was observed (L/G 50:50), 
followed by a sustained drug release (L/G 75:25). As already described PTX is a promising 
molecule for IP treatment, so PTX-containing microsphere formulations based on other 
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polymers were also developed. Paclimer® was made by incorporating PTX in a biodegradable 
poly-phosphoester polymer matrix, to form microspheres with a mean particle size of 53 µm. 
These microparticles resulted both in vitro and in vivo (after IP administration in a phase I 
study) in a sustained release of PTX over a period of 8 weeks [78]. The triblock poly (ε-
caprolactone)-poly(ethyleneglycol)-poly (ε-caprolactone) (PCL-PEG-PCL) copolymer was 
synthesized to prepare camptothecin-loaded microspheres. These microspheres were 
developed to protect camptothecin from hydrolysis, thus enhancing its treatment efficacy 
towards colorectal PC [79]. 
Nanoparticles 
Although microspheres have a longer retention time in the peritoneal cavity, they can also 
induce inflammatory reactions and peritoneal adhesions [80]. Because of these issues the 
benefit-to-risk ratio should be taken into account when deciding between microparticles and 
nanoparticles. Kohane et al. showed that nanoparticles and microparticles formulated with 
lower molecular weight polymers had a much lower incidence of peritoneal adhesions and 
were safer to use [81]. Another advantage of nanoparticles is that they can bypass drug efflux 
pumps, thus evading multi-drug resistance and achieving significantly higher drug 
accumulation in the cells compared to IP therapy with unformulated free drugs [82] [83]. 
Although conventional nanoparticles are rapidly cleared from the abdominal cavity due to 
their size, nanoparticles which respond to a wide array of stimuli such as pH, temperature, 
light and ultrasound, are being investigated. For IP therapy, paclitaxel-loaded pH responsive 
nanoparticles were developed which were designed to deliver paclitaxel intracellularly after 
endocytosis. In this formulation PTX is encapsulated in an acrylate-based polymer with a pH-
responsive 2,4,6-trimethoxybenzaldehyde protective group. These nanoparticles react to an 
endosomal pH (pH ≤5) and increase in volume to release their drug load. When these 
nanoparticles are IP injected in a mice tumor model, they remain in the peritoneal cavity for 
7 days [84]. IP chemotherapy using a nanocrystalline PTX formulation stabilized by Pluronic®F-
127 (i.e. polyethylene oxide-polypropylene oxide (PEO-PPO) block copolymer) showed a faster 
recovery of the animals compared to treatment with Taxol®, while the cytotoxicity and 
antitumor efficacy was similar [85]. In 2008 a phase I study for the IP treatment of PC of 
ovarian origin using Nanotax® was initiated, using PTX nanoparticles produced by a technique 
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known as precipitation with compressed antisolvent. In vivo studies showed that mice treated 
with Nanotax® survived significantly longer and demonstrated a reduced toxicity compared to 
the Taxol®-treated group [86].  
Liposomes 
Liposomes have been widely studied as potential carriers for hydrophilic and hydrophobic 
drugs and diagnostic agents. Due to their small size (100 – 1000 nm), liposomes have a fast 
clearance from the abdominal cavity. As such it is important to change some of the liposomes 
characteristics such as lipid composition, surface properties and charge, in order to increase 
their retention time in the abdominal cavity. Hirano et al. (1985) described that the charge of 
the liposomes is a predictive factor for the retention time [29]. When the liposomes have a 
negative charge, they were rapidly absorbed from the peritoneal cavity, while positively 
charged liposomes had a slower absorption rate. This might be attributed to electrostatic 
interaction between the positively charged liposomes and the negative surface of the 
peritoneal mesothelium, in combination with a low uptake of positive liposomes by peritoneal 
macrophages [87]. Changing the type of phospholipid (the main building block of liposomes) 
had no effect on retention time in the abdominal cavity [88], whereas the incorporation of 
polyethylenglycol (PEG) in the phospolipid membrane showed a 30% higher peritoneal 
retention by the avoidance of the macrophages present in the peritoneal cavity, compared to 
the same non-pegylated liposomes [87]. 
Micelles 
Taxol®, a micellar PTX formulation using Cremophor®EL (i.e. a polyethoxylated castor oil 
surfactant) is used for IP treatment of ovarian cancer. Taxol® showed a longer residence time 
in the abdominal cavity compared to free unformulated PTX (40.7 ± 13.8 hours vs 7.3 ± 2.8 
hours), which indicated that encapsulation is an effective way to extend the residence time of 
a drug in the abdominal cavity [89]. But as already described, Taxol® is not well tolerated as 
hypersensitivity reactions and neurotoxicity are reported due to the surfactant 
(Cremophor®EL) included in the formulation [90]. Several studies showed that the carrier 
plays an important factor in the distribution and clearance of the drugs after IP administration 
[89] [91]. In a rat model, the absorption rate of PTX and docetaxel was influenced by the 
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solubilizer in the system (Cremophor®EL and polysorbate-80 for paclitaxel and docetaxel, 
respectively). While the AUCIP of PTX doubled in comparison to docetaxel when conventional 
vehicles were used, dissolution of docetaxel in Cremophor®EL or Polysorbate-80 increased its 
retention time and yielded similar AUCIP values compared to PTX [92]. 
Table III. Advantages and disadvantages of the drug delivery systems investigated for IP 
therapy. 
 
Drug Delivery system Advantages Disadvantages 
Microspheres Prolonged retention 
Limited tumor penetration 
Risk of peritoneal adhesions 
Nanoparticles 
Passive targeting 
Avoiding multidrug resistance (MDR) 
Lower incidence of peritoneal adhesions 
Rapid clearance from 
abdominal cavity 
Liposomes 
Similar to nanoparticles 
Active targeting by varying parameters 
Similar to nanoparticles 
Micelles Prolonged retention time Increasing systemic toxicity 
Injectable systems 
Prolonged retention time 
Localized and sustained drug delivery 
Lower systemic toxicity 
Prevention against peritoneal adhesion 
Viscosity issues 
Implantable systems Similar to injectable systems 
Invasive 
Surgical expertise 
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Implants and injectable depots 
Implantable and injectable depots have been investigated for localized and sustained delivery 
of anticancer agents [93]. Those systems may be the most promising approach for the IP 
treatment of PC. The rationale of using hydrogels for IP therapy is dual as a hydrogel will retain 
the drugs within the peritoneum and will also protect against peritoneal adhesions [94]. A 
major drawback for hydrogels is achieving homogeneous distribution of the drug in the 
peritoneal cavity. Also the viscosity of the injectable hydrogels can cause problems. Low 
viscous sytems may fail to provide a delayed drug release profile, while highly viscous systems 
may be difficult to administer [93]. Because of these problems thermosensitive hydrogels are 
developed. These gels are free-flowing at room temperature and form a non-flowing gel at 
body temperature, serving as an in situ drug depot. Therefore the formulation can be easily 
mixed with the drugs and injected by a syringe as a fluid, while forming a viscous deposition 
at the target location [95]. This gelation behavior is primarily due to the formation of self-
associated micelles via hydrophobic interactions. Above the lower critical solution 
temperature, these micelles are closely packed together resulting in micellar aggregation and 
a change of rheological properties  [96]. Gong et al. reported that a hydrogel system based on 
a biodegradable poly(ethylene glycol)-poly(ε-caprolactone)-poly(ethylene glycol) (PEG-PCL-
PEG, PECE) triblock copolymer could be used as delivery vector of chemotherapeutic drugs for 
IP infusion chemotherapy. The system was loaded with 5-FU [97] and doxorubicin [98]. When 
the system was infused intraperitoneally in mice, the formed gel phase guaranteed a delayed 
drug release up to 48 hours after injection. 
Implantable systems were developed for IP treatment of ovarian cancer. This implant is 
composed of paclitaxel-loaded poly-D,L-lactide and poly(lactide)-block-poly(ethylene glycol) 
(PLA-b-PEG) particles dispersed throughout a chitosan egg-phophatidylcholine matrix. This 
formulation provided a sustained and localized release of 1% PTX per day in mice over a period 
of 3 months [99, 100]. The implants have a higher efficacy, and are less toxic and more 
biocompatible than Taxol®. Although the implantable systems have promising results, the 
biggest issue for using those systems is the need for surgical expertise to implant the system. 
  
 HIPEC as treatment for intraperitoneal carcinomatosis of ovarian origin Ι Introduction 
 
 29 
 
Carrier solutions 
A simple approach to improve IP administration of chemotherapeutic agents using 
conventional formulations is varying the medium in which the drug is dissolved or suspended. 
The volume of the fluid in which the chemotherapeutic agent is dissolved plays an important 
role towards drug distribution in the peritoneal cavity. The ideal carrier solution for IP 
chemotherapy should expose all cancerous surfaces or residual tumor cells to high levels of 
cytotoxic agents for as long as possible and ensure a uniform distribution of the drug in the 
abdominal cavity. Small volumes of fluid do not flow freely in the peritoneum, even with 
multiple position changes of the patients [101], while large volumes (>2 L/m2 body surface 
area) which cause moderate abdominal distention result in more uniform intraperitoneal drug 
distribution. Hence maintaining a high volume of the intraperitoneal liquid would improve the 
effectiveness of the treatment as the choice of the solution, in which the drug is administered, 
plays an important role in the distribution of the drugs [102] [103]. Current techniques for IP 
chemotherapy administration mainly use isotonic electrolyte solutions (e.g. 5% glucose, 0.9% 
sodium chloride). However isotonic salt and dextrose solutions are rapidly absorbed due to 
their low molecular weight [103, 104] [102] which decreases the distribution of the drug in 
the peritoneal cavity. Hypotonic solutions showed promising in vitro results as they increased 
cytotoxicity and accumulation of cisplatin in tumor cells [105]. However, the clinical results 
were negative as bleeding and thrombocytopenia occurred, while no pharmacokinetic 
advantages were observed [106] [107]. When hypertonic solutions were used, a prolonged 
retention time of the intraperitoneal volume was achieved, but their main disadvantage is the 
dilution of the intraperitoneal drug due to fluid shift to the peritoneal cavity [102]. 4% 
icodextrin, a colloid osmotic agent of α-1,4 linked glucose polymers, has been successfully 
used to prolong retention of intraperitoneal chemotherapy, the solution can remain 3 to 4 
days in the peritoneum [108]. Another iso-osmolar solution, with a potentially long 
intraperitoneal dwell time, is 6% hydroxyethyl starch (hetastarch) which has been successfully 
used to prolong intraperitoneal retention of gemcitabine and paclitaxel in animal studies [102, 
109]. Also the use of HAES-steril®, a starch-based carrier solution, reduced the clearance of 
the chemotherapeutic solutions from the peritoneal cavity compared to physiological saline 
solution [110].   
 HIPEC as treatment for intraperitoneal carcinomatosis of ovarian origin Ι Introduction 
 
  
30  
 
4. Rationale of hyperthermia 
As already described intraperitoneal chemotherapy is a promising technique for the treatment 
of PC. In most institutions hyperthermia is a standard component of the surgical procedures 
of the treatment. Hyperthermia is defined as an increase of temperature in a tumor-affected 
body region to 39 – 43 °C by using an external energy source [111]. The efficacy of 
hyperthermia is shown in different in vitro studies. In the 1960s it was thought that heat acts 
similarly to radiation by directly damaging nuclear DNA [112]. In 1986, Borrelli et al. described 
the occurrence of “membrane blebbing” which is a typical feature of apoptosis [113]. 
Currently several mechanism are known which argument the efficacy of hyperthermia: 
- Cytoskelet 
o Changes in stability and fluidity of cell membrane 
o Alterations of cell shape 
o Impaired transmembrane transport 
o Alteration of membrane potential 
o Modulation of efflux pumps 
o Induction of apoptosis 
- Intracellular proteins 
o Impairment of protein synthesis 
o Denaturation of proteins 
o Aggregation of proteins at nuclear matrix 
o Induction of HSP-synthesis 
- Nucleic acids 
o Decrease of RNA/DNA synthesis 
o Inhibition of RNA/DNA enzymes 
o Altered DNA-conformation 
- Other alteration of cell function 
o Intracellular metabolism of other substrates 
o Gene expression, signal transduction 
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Another observation was that hyperthermia not only acts in a cytotoxic way in itself but also 
sensitizes tumor cells to radiotherapy (thermal radiosensitization) and various cytostatic drugs 
(thermal chemosensitization). Conflicting results have been reported from in vitro and in vivo 
studies on the combination of PTX with hyperthermia (Table IV).  
Table IV. Impact of hyperthermia on paclitaxel activity. 
In vitro 
Study 
Temperature 
(°C) 
Thermal 
enhancement 
Cell type 
Michalakis [37] 41.5 – 43 - Ovarian adenocarcinoma (SKOV-3) 
Mohammed [109] 41.5 + Murine fibrosarcoma (Fsa-II) 
Othman [114] 43 + Murine breast cancer (FM3A) 
Knox [115] 42 - Human cytotoxic T-lymphocytes 
Rietbroek [116] 42 – 43 - Human squamous lung cancer 
Leal [117] 43 - Human breast adenocarcinoma (MCF-7) 
Van Bree [118] 41 - Human colorectal cancer  
In vivo 
Sharma [119] 43 + Murine melanoma cells (B16F10) 
Cividalli [120] 43 + Murine mammary carcinoma (CH3/TIF) 
Mohamed [109] 41.5 - Murine fibrosarcoma (Fsa-II) 
Bouquet [121] 43 - Colorectal cancer (CC531s) 
 
The rationale for the use of hyperthermia with taxanes is based on the fact that mild 
hyperthermia resulted in a disorganization of the microtubule system, and taxanes are 
considered microtubule stabilizing agents. Thus, a common target of cytotoxic damage is 
involved. Mohamed et al. (2003) showed that when PTX was combined with hyperthermia, 
there was a statistically significant decrease in tumor growth at low doses when compared 
with PTX alone [109]. Michalakis et al. showed that cell death mechanisms were different after 
hyperthermic treatment as a significantly higher amount of cell necrosis was observed 
compared to the normothermic treated cells. Despite the increased cell necrosis, the number 
of viable cells remained unchanged [37, 38]. Nevertheless, they suggest that a combination of 
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PTX and hyperthermia supported clinical relevance as the induced necrosis increased local 
inflammation and recruited resources of the immune system.   
In vitro and in vivo results often differed, with factors such as tumor physiology, 
microcirculation, pH and hypoxia playing an essential role in the interaction between 
hyperthermia and different cytotoxic agents. Major investigators on this issue have stated that 
drug concentrations at the target must be high to allow sufficient thermal enhancement. 
These conditions are met during HIPEC. But other studies have shown that the use of HIPEC 
can cause side effects such as bone marrow suppression, renal failure, anastomic leakage and 
bowel perforation. Anastomic leakage and bowel perforation are related with the applied 
temperature, the risk of damage increased at higher temperature (>43 °C) or when there is 
long contact time between heat and tissue. 
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DEVELOPMENT OF A NANOCRYSTALLINE PACLITAXEL 
FORMULATION FOR HIPEC TREATMENT 
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INTRODUCTION 
Ovarian cancer is the fifth most common cancer affecting European women [1]. Once the 
tumor starts growing in the ovary, spread of cancer cells throughout the abdominal-pelvic 
cavity occurs very early in the development of the disease [2]. The standard therapy for 
patients with peritoneal carcinomatosis of ovarian origin is initial cytoreductive surgery 
followed by intravenous platinum-taxane chemotherapy [3, 4]. Lately, this standard therapy 
has been modified as alternative treatments have been developed. A treatment following 
cytoreductive surgery is hyperthermic intraperitoneal chemotherapy (HIPEC) is a new 
treatment strategy with promising results. Administration of chemotherapy intraperitoneally 
under hyperthermic conditions may improve the mean overall survival of patients with 
advanced ovarian cancer from 19.0 to 76.1 months [5]. PTX is a suitable molecule for HIPEC 
treatment as it has a high peritoneal/plasma concentration ratio (>1000) and a significant first 
pass effect [6]. However, PTX is not commonly used for HIPEC treatment because of the side 
effects caused by Cremophor®EL used as solubilizer in the commercially available formulation 
Taxol®, like abdominal pain and life-threatening hypersensitivity reactions [7]. Due to these 
side effects a lot of research is done, developing new PTX formulations without resorting to 
toxic excipients to improve the solubility of PTX.  
As size reduction is an efficient method to improve the performance of poorly soluble drugs 
(the increased surface area of smaller particles enhances dissolution rate and bioavailability 
based on the Noyes-Whitney equation), wet milling was used to obtain a nanosuspension of 
paclitaxel. While both top-down (particle size reduction) and bottom-up (precipitation 
method) techniques can be used to manufacture nanoparticles [8], wet milling is a typical top-
down method using milling beads to grind the particles. This procedure is known as an efficient 
method to prepare nanoparticles with easy scale-up and limited batch-to-batch variability 
when the method is optimized. Contamination of the final product due to erosion of the 
milling beads is a main concern, while changes in physical form or amorphization can also be 
an issue during wet milling [9]. As breakage of drug crystals into nanoparticles significantly 
increases particle surface area, the higher Gibbs free energy creates a thermodynamically 
unstable nanosuspension, and proper selection of a stabilizer is required during the 
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preparation of the nanosuspension to prevent agglomeration or crystal growth (due to 
Ostwald ripening) of the nanoparticles [10]. 
In this study, the wet milling technique is applied to obtain a PTX nanosuspension stabilized 
with a surfactant (polyethylene oxide-polypropylene oxide block copolymers, Pluronic®F-68 
and  
Pluronic®F-127). Pluronic-stabilized PTX nanocrystals have already been formulated, but were 
characterized by a low drug-to-stabilizer ratio, Lui et al. required at least a PTX/Pluronic®F-127 
ratio of 1/5, as at lower stabilizer concentrations stable nanocrystals could not be formed [11]. 
In order to maximize the drug concentration at the delivery site, which is one of the challenges 
of HIPEC therapy [12], the stabilizer content in the nanocrystalline formulation was minimized 
in our study. After characterization of the nanocrystals processed via the wet milling 
technique, the feasibility of the nanosuspension for HIPEC treatment was assessed (in 
comparison with Taxol®) by evaluating in vitro cytotoxicity of the excipients as well as the 
formulation on an ovarian cancer cell line, while the toxicity, bioavailability and effect on 
tumor growth were tested in a rat model.  
MATERIALS AND METHODS 
Materials 
Paclitaxel (PTX) was purchased from Enzo Life Sciences (Zandhoven, Belgium). Polyethylene 
oxide-polypropylene oxide (PEO-PPO) block copolymers, Pluronic®F-68 and Pluronic®F-127, 
were obtained from BASF (Ludwigshafen, Germany), Taxol® from Bristol-Myers Squibb 
(Brussels, Belgium) and Cremophor®EL from Alpha Pharma (Waregem, Belgium). 
Preparation of paclitaxel nanocrystals 
PTX nanosuspensions were prepared by a wet milling technique using two different stabilizers 
(Pluronic®F-68 and Pluronic®F-127) in three PTX/stabilizer ratios (2/1, 4/1 and 8/1). After 
dissolving the stabilizer in a 20 ml vial containing 5 ml of 0.9% NaCl, PTX powder (50 or 100 
mg) was dispersed in this aqueous phase. Zirconium oxide beads (amount 30 g, diameter 0.5 
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mm) were added to the suspension as milling pearls. The vials were placed on a roller-mill 
(Peira, Beerse, Belgium) and grinding was performed at 150 rpm for 24 or 60 hours. After 
milling, the nanoparticles were separated from the grinding pearls by sieving.  
For solid state characterization of the PTX nanocrystals, the nanosuspension was freeze dried 
for 24 hours at -50 °C and 1 mbar. 
Nanocrystal characterization 
The mean particle size and polydispersity index (PI) of the nanosuspensions was determined 
by photon correlation spectroscopy, using a Zetasizer 3000 (Malvern Instruments, 
Worcestershire, UK). Prior to analysis, the nanosuspensions were diluted with distilled water 
and were analysed at room temperature. 
The morphology of the freeze dried drug particles was observed under a scanning electron 
microscope (SEM) (JSM 5600 LV, Jeol, Tokyo, Japan) after coating the powder particles with 
platinum using a sputtering equipment (Auto Fine Coater, JFC-1300, Jeol, Tokyo, Japan). 
Thermal properties of the freeze dried samples were analysed by differential scanning 
calorimetry (DSC Q2000, TA instruments, Leatherhead, UK). Samples were placed in sealed 
aluminum pans, and evaluated over a temperature range from -20 to 190 °C with a heating 
rate of 10 °C/min. Pure drugs and physical mixtures were tested as controls. The thermal 
profiles were analysed using TA Instruments Universal Software.  
In vitro cytotoxicity 
The human ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture 
Collection) was cultured at 37 °C in a 5% CO2-containing humidified atmosphere in McCoys 
medium (Invitrogen, Merelbeke, Belgium). The medium was supplemented with 10% fetal 
bovine serum, penicillin, streptomycin (Invitrogen, Merelbeke, Belgium) and fungizone (Bristol 
Myers Squibb, Brussels, Belgium). 
The cytotoxicity of PTX nanosuspensions (at a PTX/Plu F127 ratio of 4/1) and Taxol® was tested 
at PTX concentrations of 0.01, 0.1, 1, 5 and 10 µg/ml and 8 wells per concentration were used. 
Development of a nanocrystalline paclitaxel formulation for HIPEC treatment Ι Chapter 1 
 
  
50  
 
Both Taxol® and PTX nanosuspensions were diluted with 0.9% NaCl to the appropriate 
concentration. In addition, the cytotoxicity of the excipients in these formulations (Pluronic®F-
127 and Cremophor®EL) was tested using 9 concentrations: 0, 0.01, 0.1, 1, 1.5, 2, 2.5, 3 and 
3.5 mg/ml.  
To evaluate the cytotoxicity, 20x103 cells/ml were seeded in 96-well plates (Sarstedt, Newton 
NC, USA). After 72 hours, 20 µl medium was removed and replaced by the test formulation. 
After incubation for 1 hour at 41.5 °C (i.e. to mimic the HIPEC procedure used during in vivo 
studies), the medium was entirely removed, cells were washed with phosphate buffered saline 
(PBS) and 200 µl fresh medium was placed in each well. Afterwards, the cells were incubated 
for 24 and 96 hours at 37 °C under 5% CO2-atmosphere. The cytotoxicity of the test 
formulations was determined via MTT assay and compared with the non-treated cells. 100 µl 
medium was replaced by 100 µl MTT-reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-difenyl-
tetrazolium bromide, at a concentration of 1 mg/ml PBS-D+). The reagent was mixed and 
incubated in dark conditions for 2 hours at 37 °C. Afterwards all medium was removed and 
200 µl DMSO (Acros Organics, Geel, Belgium) was added to dissolve the formed formazan. 
After incubation of the plates for 1 hour at 37 °C, the optical density was measured at 570 nm 
normalizing with a reference wavelength of 650 nm using an ELISA-plate reader (Paradigm 
Detection Platform, Beckman Coulter, Suarleé, Belgium). 
In vivo testing 
HIPEC procedure 
Adult female athymic nude rats (Harlan, Horst, The Netherlands) were kept in standard 
housing conditions with water and food ad libitum and a 12 hours light/dark circle. All animal 
experiments were approved by the Ethical Committee of the Faculty of Medicine, Ghent 
University (ECD 09/06). 
After anesthetizing each rat with 3% isoflurane (Forene®, Abbott, Waver, Belgium) a vertical 
incision was made along the midline in the abdominal wall muscle. The abdominal wall muscle 
was attached to a metal ring which was placed a few centimeters above the incision. The inlet 
and outlet tubing (Pumpsil®, Watson-Marlow, Zwijnaarde, Belgium) was placed in the 
Development of a nanocrystalline paclitaxel formulation for HIPEC treatment Ι Chapter 1 
 
 51 
 
peritoneal cavity for perfusion with the cytostatic solution over a period of 45 min. A roller 
pump (Watson-Marlow, Zwijnaarde, Belgium) circulated the cytostatic solution through a heat 
exchanger set at 41.5 °C. During perfusion, the perfusate solution and body temperature of 
the rat were closely monitored and data was collected using E-Val® 2.10 Software (ELLAB®, 
Roedovre, Denmark). After HIPEC, the cytostatic perfusate solution was removed and the 
incision was sutured. 
 
 
 
 
 
 
 
 
Figure 1. Athymic nude rat which underwent a HIPEC procedure (A) and the equipment for the HIPEC 
procedure, from the left to the right, the roller pump, heat exchanger and temperature sensor (B). 
Maximum tolerated dose  
The maximum tolerated dose (MTD) was determined for both PTX formulations (Taxol® and 
PTX/Plu F127 nanosuspension (ratio 4/1)). The MTD was defined as the highest non-lethal 
dose with a maximum reduction of body weight of 10% after 2 weeks of HIPEC treatment. The 
test procedure was based on the Organization for Economic Co-operation and Development 
(OECD) guidelines. Based on the MTD of Taxol® (0.24 mg/ml) determined by Bouquet et al. in 
WAG/Rij rats [13], a PTX dose of 0.21 mg/ml was used as starting point. To determine MTD, 
the PTX concentration in the formulation was gradually increased (increments of 0.03 mg/ml) 
using 1 rat per concentration. When mortality occurred, 3 more rats were tested at the highest 
A B 
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non-lethal dose to confirm MTD. MTD of both formulations was determined using HIPEC 
settings (i.e. 41.5 °C during 45 min). The PTX nanosuspensions as well as Taxol® were diluted 
with 0.9% NaCl to obtain the correct dose in an isotonic solution. 
Bioavailability 
Blood was sampled in heparin-containing tubes via a catheter which was placed in the arteria 
carotis. Blood samples were taken at 0, 15, 30, 45, 60 and 90 min after starting the perfusion. 
Perfusate samples were collected at 0, 15, 30 and 45 min after starting the perfusion and the 
PTX concentration was measured via HPLC, to ensure that an accurate dose was administered 
during the HIPEC procedure. After the bioavailability study the rats were euthanized. Blood 
samples were centrifuged immediately afterwards, and separated plasma was stored frozen 
at -20 °C until analysis. 
The perfusate samples were analysed by high performance liquid chromatography (HPLC). The 
HPLC-system (Merck-Hitachi, Tokyo, Japan) consisted of a pump (L-6000), an integrator (D-
2000), an autosampler (L-7200) with a 25 µl loop and a UV/VIS detector (L-4200). Detection 
was performed at 227 nm. To achieve chromatographic separation a guard column 
(Lichrospher® 100-RP-18, 4*4 mm (5 µm), Merck, Darmstadt, Germany) and an analytical 
column (Lichrospher® 100-RP-18, 125*4 mm (5 µm), Merck, Darmstadt, Germany) were used. 
The mobile phase consisted of acetonitrile (Biosolve, Valkenswaard, The Netherlands) and 
0.1% (v/v) phosphoric acid in ultrapure water (Acros Organics, Geel, Belgium) (42:58, v/v) 
degassed by ultrasonication under vacuum.  
Frozen plasma samples, calibrator samples and quality control (QC) samples were allowed to 
thaw at room temperature. For samples within the assay range a volume of 50 µl was 
transferred to an empty well of a 96-well filtration plate. Other samples (samples above upper 
limit of quantitation) were diluted sixfold with blank rat plasma prior to the analysis. 
Subsequently 200 µl of acetonitrile containing internal standard (C13-paclitaxel) was added. 
After vacuum filtration, the filtrate was diluted with 150 µl of water and injected onto the 
Waters Acquity UPLC system for analysis. After chromatographic separation on a Waters 
Acquity UPLC BEH C18 column (100 mm x 2.1 mm, 1.7 µm particle size), PTX and the internal 
standard were detected using a Waters Quattro Ultima triple quadrupole system (Micromass 
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Waters, Manchester, UK). The validation of the method was conducted with reference to the 
FDA’s guidance for bioanalytical method validation. The calibration curve was constructed by 
least squares linear regression of the peak area ratio of PTX/internal standard against nominal 
concentration with a weighting of concentration-1. The measurement range of the analytical 
method was 2.0 – 500 ng/mL for PTX in rat plasma. The range was further extended up to 3 
µg/ml by appropriately diluting plasma samples prior to analysis. Total imprecision and 
trueness were calculated on results of repeated analysis of quality controls on different days. 
For all levels of the QC samples, imprecision and trueness measurements comply with the FDA 
guidance specifications on maximum tolerable bias and imprecision. 
Tumor growth delay  
Donor rats were injected with 30x106 SKOV-3 cells between the peritoneum and the 
abdominal muscle. The animals received daily subcutaneous cyclosporine injections (dose: 3 
mg) over a period from 3 days prior until 10 days after tumor cell injection. After 3 to 4 weeks, 
a tumor was induced, but this tumor remained localized and did not (or not completely) 
penetrate the peritoneum. Therefore parts of the tumor induced in the donor rats (5 x 5 mm, 
with a thickness of 3 mm) were transplanted on the peritoneum of acceptor rats. The acceptor 
rat also received daily subcutaneous cyclosporine injections (dose: 3 mg) from 3 days prior 
until 10 days after tumor transplantation to ensure tumor attachment. Two weeks after 
transplantation, the tumor had attached to the peritoneum and had sufficiently grown to 
perform the tumor growth delay (TGD) experiment. 
The effect of the PTX formulations (Taxol® and nanosuspension) on tumor growth was 
evaluated via a Siemens® Trio 3T MRI (Erlangen, Germany). Prior to the MRI scan, the rats 
were anaesthetized with Rompun 2% (Bayer, Diegem, Belgium) and ketamine 1000 CEVA 
(Ceva, Amersham, UK) using a dose of 10 mg/kg and 90 mg/kg, respectively. The rats were 
placed prone in a (wrist) coil to measure the tumor volume. A T1-weighted 3D FLASH sequence 
was applied with a flip angle of 10°, a repetition time of 13 ms and an echo time of 4.9 ms to 
obtain a voxel size of 0.19 x 0.19 x 0.4 mm3. In order to easily locate the tumor, the rat was 
palpated and a vitamin B12 pellet was attached to the skin where the tumor was located. 
Tumor volume was calculated using PMOD software (PMOD Technologies, Adliswil, 
Switserland). Rats were scanned 1 day before HIPEC treatment (day 0) to measure the initial 
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volume of the tumor. At day 1 the rats were treated with Taxol® or the nanocrystalline PTX 
formulation. Tumor volume was evaluated 7 and 14 days after HIPEC treatment to monitor 
the effect of both PTX formulations. 
Statistical analysis 
Statistical Program for Social Scientists (SPSS 19.0) was used to analyse the results. 
For the bioavailability study, the pharmacokinetic parameters of both groups were compared 
using an unpaired sample t-test with a significance level of 0.05. 
For the TGD study, data of day 0 were used as reference (100%). The different treatment 
groups were compared with each other on day 7 and 14 using a one-way ANOVA with a 
significance level of 0.05. Bonferroni post-hoc analysis was performed for pairwise 
comparisons between treatment groups. 
RESULTS AND DISCUSSION 
Physico-chemical characterization of PTX nanocrystals 
Pluronic®F-68 and Pluronic®F-127 were selected as stabilizers because these block copolymers 
have already been successfully used to stabilize PTX nanosuspensions (both at a higher 
surfactant/PTX ratio than used in this study) [11]. In addition, these surfactants are known to 
increase the solubility of low soluble drugs, and have cytotoxicity-promoting properties as 
they interact with multi-drug resistance cancer tumors, resulting in drastic sensitization of 
these tumors to the cytostatic drugs [14-16]. A wet milling cycle during 24 hours did not yield 
nanocrystalline PTX when Pluronic®F-68 was used as stabilizer (independent of the 
PTX/stabilizer ratio) (Table I).  
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Table I. Mean particle size ± SD (nm) and polydispersity index after wet milling (at 150 rpm) of 
a paclitaxel suspension. 
Stabilizer 
PTX/Stabilizer 
ratio (w/w) 
Amount PTX 
(mg) 
Milling time 
(hours) 
Size ± SD (nm) PI 
Pluronic®F-68 
2/1 100 24 4057 ± 1042 0.368 
4/1 100 24 3374 ± 1731 0.421 
8/1 100 24 3208 ± 765 0.470 
Pluronic®F-127 
2/1 100 24 417 ± 72 0.351 
4/1 100 24 462 ± 128 0.308 
8/1 100 24 812 ± 154 0.425 
2/1 100 60 420 ± 18 0.260 
4/1 100 60 440 ± 30 0.268 
8/1 100 60 462 ± 66 0.302 
2/1 50 60 325 ± 12 0.224 
4/1 50 60 307 ± 12 0.232 
8/1 50 60 375 ± 21 0.287 
 
In contrast, Pluronic®F-127-containing formulations were efficiently ground into 
nanosuspensions. Although Pluronic®F-68 and F-127 have the same basic PEO-PPO-PEO 
structure, they differ in the number of PEO and PPO groups. The higher molecular weight and 
lower hydrophilic-lipophilic balance (HLB) value of Pluronic®F-127 compared to Pluronic®F-68 
allowed more interaction between the amphiphilic surfactant and the nanoparticle surface, 
providing sufficient steric hindrance to stabilize the nanoparticles and prevent particle 
agglomeration [17]. However, a minimum concentration of stabilizer was required as at the 
lowest Pluronic®F-127 content (i.e. PTX/stabilizer ratio of 8/1) the surfactant failed to 
sufficiently stabilize the PTX particles. A longer milling time (60 hours) not only yielded PTX 
nanocrystals at all PTX/Pluronic®F-127 ratios, it also resulted in a narrower particle size 
distribution as indicated by the lower polydispersity indices (PI).  
Reducing the PTX amount during wet milling to 50 mg improved the efficiency of the milling 
process as all formulations yielded a mean particle size below 400 nm, in combination with 
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analysis showed a significant reduction in particle size compared to unmilled PTX (>5 µm), as 
a size around 400 nm was obtained, which confirms the results obtained by particle size 
analysis (Fig. 2).  
 
 
 
 
 
Figure 2. SEM images of (A) unmilled paclitaxel and (B) freeze dried paclitaxel nanocrystals, processed 
via wet milling (150 rpm for 60 hours), using a paclitaxel load of 50 mg per vial and a PTX/stabilizer 
ratio of 4/1. Pluronic®F-127 was used as stabilizer. 
Solid state characterization by DSC of the freeze dried nanocrystalline formulation showed 
that the crystallinity of PTX was not affected by the wet milling process (Fig. 3). As no 
crystalline-to-amorphous transitions were observed, the friction generated during the wet 
milling process did not create stability issues [18].  
 
 
 
 
 
 
Figure 3. Differential scanning calorimetry profiles of paclitaxel (A), Pluronic®F-127 (B), physical 
mixture (C) and PTX/Plu F127 4/1 nanocrystals (D). 
A B 
A 
B 
C 
D 
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A 6 month stability study at ambient conditions of the different PTX/Plu F127 formulations 
(Fig. 4) indicated that initially the particle size of all 3 formulations slightly increased. 
Afterwards the particle size of PTX/Plu F127 2/1 and 4/1 nanocrystals remained constant (± 
400 nm) with PI values staying below 0.3. In contrast, the PTX/Plu F127 8/1 formulations 
became polydispers (PI>0.5) and particle agglomeration was observed. Due to these stability 
issues the PTX/Plu F127 8/1 formulations was not used in further experiments. As the goal of 
this study was to reduce the stabilizer concentration in the nanosuspensions, the PTX/Plu F127 
4/1 formulation was selected for further in vitro and in vivo experiments.  
 
Figure 4. Particle size (mean ± SD) of PTX nanosuspensions as a function of storage time at ambient 
conditions. PTX/Plu F127 ratio: (●) 2/1 , (■) 4/1, (▲) 8/1 
In vitro cytotoxicity  
The cytotoxicity of the PTX formulations (Taxol® and the nanosuspension) as well as the 
cytotoxicity of the excipients (Pluronic®F-127 and Cremophor®EL) was tested on human 
ovarian carcinoma cells (SKOV-3) as ovarian cancer commonly results in PC which can be 
treated via HIPEC. As the main drawback to the use of Taxol® for HIPEC treatment are the side 
effects caused by its excipient Cremophor®EL, the cytotoxicity of Cremophor®EL and 
Pluronic®F-127 was compared in a concentration range from 0.01 to 3.5 mg/ml. After 1 hour 
incubation, there was no reduction of cell viability at the lowest concentration (Fig. 5).  
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Figure 5. Viability (mean ± SD) of the SKOV-3 cell line after application of different concentrations of 
Cremophor®EL (■) and Pluronic®F-127 (●) at hyperthermic conditions (41.5 °C) (n=8 wells per 
concentration).  
However, at higher concentrations the cell viability decreased after contact with 
Cremophor®EL while the cells treated with Pluronic®F-127 remained unaffected, indicating a 
significantly lower cytotoxicity of Pluronic®F-127 compared to Cremophor®EL. Despite the 
differences between the two excipients, both PTX formulations were equipotent, as the 
cytotoxicity of the new nanosuspension was equal to Taxol® (Fig. 6).  
Nanocrystalline PTX formulation for HIPEC treatment 
The maximum tolerated dose (MTD) of both PTX formulations after HIPEC was determined by 
monitoring the survival rate and body weight of the rats following HIPEC treatment. While at 
a PTX dose of 0.21 and 0.24 mg/ml the rats regained their initial body weight after 2 weeks, a 
PTX concentration of 0.27 mg/ml for Taxol® and the nanosuspension resulted in mortality. 
Hence, 0.24 mg/ml was set as MTD for both formulations. At this concentration no significant 
differences were observed between both treatments based on the weight of the rats 2 weeks 
after treatment. However, rats treated with the PTX nanosuspension recovered faster 
compared to the group treated with Taxol® as they already regained their initial body weight 
5 days after HIPEC treatment, highlighting the advantage of using the non-cytotoxic 
Development of a nanocrystalline paclitaxel formulation for HIPEC treatment Ι Chapter 1 
 
 59 
 
Pluronic®F-127. Based on the body surface area, the MTD corresponded to a dose of 
960 mg/m2, which is much higher compared to the dose administered to humans (175 mg/m2) 
during HIPEC [19]. This underlines one of the opportunities of HIPEC: the possibility to use 
higher doses, resulting in higher local concentrations which are maintained for a longer time 
in the abdominal cavity and which have a higher direct cytotoxic effect [20].  
 
Figure 6. Viability (mean ± SD) of the SKOV-3 cell line (n=3 and 8 wells per concentration) after 
application of different paclitaxel concentrations delivered under hyperthermic conditions (41.5 °C) 
via (■) Taxol® and (●) PTX/Plu F127 4/1 nanosuspension. MTT after 24 hours (A) and 96 hours (B). 
During HIPEC treatment, a sample of the perfusate was taken every 15 min in order to monitor 
the delivered PTX concentration. Statistical analysis showed no differences between the 
applied concentration of the different formulations (p=0.348). 
Monitoring the PTX plasma concentrations over a 90 min period (Fig. 7) showed similar 
concentrations for Taxol® and the PTX nanosuspension during the perfusion period. However, 
when the cytotoxic agent was removed after HIPEC treatment (i.e. after 45 min) the PTX 
plasma concentrations of the nanosuspension increased, while PTX plasma levels after Taxol® 
treatment remained constant during the entire monitoring period (i.e. 90 min). The enhanced 
absorption of PTX was also reflected in the pharmacokinetic parameters after perfusion with 
the PTX nanosuspension: in comparison to Taxol®, Cmax was significantly higher (124.7 ng/ml 
vs. 42.0 ng/ml, p=0.03), and AUCPl, t= 90 min was 1.5-fold higher but not significantly different 
(95% CI 3.8 ± 1.06 µg.min/ml vs. 2.5 ± 0.212 µg.min/ml).  
B A 
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Figure 7. Paclitaxel plasma concentration (mean ± SD) (ng/ml) in rats (n=6) during and post-HIPEC 
treatment with a PTX concentration of 0.24 mg/ml delivered via () Taxol® and (▲) a PTX/ Plu F127 
4/1 nanosuspension.  
Previous research already described that nanoparticles (>50 nm) can adhere to mucosa, and 
thus prolonging the contact time of the drug and enhancing its absorption [10]. Prolonged 
retention of PTX in the peritoneal cavity (in combination with enhanced PTX penetration) can 
offer a therapeutic advantage as tumor cells are exposed to higher local drug levels for a 
longer time. This approach overcomes one of the limitations of conventional intraperitoneal 
(IP) drug therapy where drugs are rapidly cleared from the peritoneal cavity [12].  
The effect of the PTX nanosuspension on tumor growth was evaluated via a tumor growth 
delay study, using Magnetic Resonance Imaging (MRI) as imaging technique to monitor tumor 
volume in a rat model. Although peritoneal carcinomatosis is characterized by a spread over 
the entire abdominal cavity, the rats were implanted with a single tumor nodule to simplify 
the tumor growth analysis (Fig. 8).  
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Figure 8. Transverse MRI images of a rat with a peritoneal tumor (situated under the vitamin B12 
pellet). The volume of interest (VOI) consists of a stack of planar regions of interest (ROI’s) (A->L). 
At day 7 and 14 after HIPEC treatment with the PTX formulations, tumor growth was 
significantly different compared to the non-treated group (p=0.001 and 0.02 for Taxol®, and 
0.003 and 0.010 for the PTX nanosuspension at day 7 and 14, respectively). No significant 
differences were observed between both PTX formulations (p=1.000 and p=0.929 at day 7 and 
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day 14, respectively) (Fig. 9). The effect of the PTX/Plu F127 nanosuspension on the tumor 
volume was similar to Taxol®. At day 7, tumor volume was reduced for both PTX formulations, 
although the results were not significantly different from the tumor volume at day 0 (p= 0.104 
and 0.097 for Taxol® and the nanosuspension, respectively). At day 14, the tumor volume had 
increased compared to the volume at day 7 and was not significantly different from the initial 
tumor volume. Although little is known about the penetration of drugs in solid tumors, 
cytotoxic agents penetrate only a few millimeters into the tumor tissue, mostly via diffusion 
[21]. Due to the limited penetration of anticancer drugs in solid tumors, IP chemotherapy in 
the abdominal cavity is only effective in micrometastases or tumors smaller than 5 mm in 
diameter [22]. Hence, HIPEC could not completely eradicate the solid tumor implanted in the 
rat model and 14 days after treatment the tumor volume had increased as a result of 
proliferation of the remaining tumor cells. However, in clinical practice cytoreductive surgery 
precedes HIPEC treatment, while HIPEC is used to remove the remaining tumor cells which 
are not visible and also to prevent the implantation of tumor cells at the resection site and on 
other abdominal and pelvic surfaces [2]. Therefore, it is likely that in practice HIPEC using a 
PTX nanosuspension will remove all remaining microscopic tumors. 
 
Figure 9. Tumor volume (mean ± SD) (%) compared to day 0, measured by MRI, 7 days and 14 days 
after HIPEC treatment with no treatment, Taxol® and PTX/Plu F127 4/1 nanosuspension (n=6). 
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CONCLUSION 
A stable nanocrystalline paclitaxel formulation was developed via the wet milling technique 
using a high paclitaxel-to-stabilizer ratio. The cytotoxicity and antitumor efficacy in a rat model 
with peritoneal carcinomatosis of ovarian origin was similar to Taxol®. However, the 
advantage of using a non-cytotoxic excipient (Pluronic®F-127) in the nanosuspension was 
reflected by the faster recovery of the rat after HIPEC treatment.  
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CHEMOTHERAPY: IS THERE AN ADDITIONAL EFFECT 
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INTRODUCTION 
Ovarian cancer is the fifth most frequent cancer in females with approximately two thirds of 
the patients also presenting advanced disease, i.e. peritoneal carcinomatosis [1, 2], since the 
spread of cancer cells throughout the abdominal-pelvic cavity occurs very early in the 
development of the disease [3]. As ovarian cancer with tumor nodules on peritoneal surfaces 
can remain confined to the peritoneal cavity for a prolonged period of time without 
dissemination to other organs or regions, it makes peritoneal carcinomatosis of ovarian origin 
a good candidate for regional cancer treatment. Cytoreductive surgery followed by local 
intraperitoneal chemotherapy (IPEC) offers acceptable morbidity and mortality rates and 
increases the 5-year overall survival [4, 5]. The major goal of IPEC is to maximize the drug 
concentration in the abdominal cavity, in particular to target the tumor, while the systemic 
exposure is minimized [6]. Following IPEC a difference in drug concentration between the 
abdominal cavity and the systemic circulation occurs because drug transport from the 
peritoneal cavity to plasma (peritoneal clearance) is generally low, due to the presence of the 
peritoneal plasma barrier. In regional therapy the drug is delivered directly to the tumor, 
hence the therapeutic effect depends on the ability of the drug to penetrate in the tumor.  
Hyperthermia, defined as an increase of temperature in the tumor-affected body region to 39 
– 43 °C [7], is thought to increase drug penetration in solid tumors thereby increasing the 
cytostatic efficiency [8, 9]. Next to a direct cytotoxic effect, hyperthermia is believed to 
enhance the antitumor effect of several cytostatic agents by increasing tumor blood supply 
and oxygenation. It remains unclear if chemotherapy must be combined with hyperthermia 
to have a positive outcome on efficacy as it is known that hyperthermia causes serious side 
effects such as bone marrow suppression, renal failure, anastomic leakage and bowel 
perforation [10, 11].  
PTX is a naturally occurring product extracted from the bark of the Taxus Brevifolia and is 
widely used for the treatment of breast, lung and advanced ovarian cancer [12]. The choice 
for PTX as drug for regional treatment of ovarian cancer is rational, because of its favorable 
pharmacokinetics as it has a high peritoneal/plasma concentration ratio (>1000) and a 
significant first pass effect [13]. Conflicting results have been reported from in vitro and in vivo 
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studies on the combination of PTX with hyperthermia [1]. The rationale for the use of 
hyperthermia with taxanes is based on the fact that mild hyperthermia results in a 
disorganization of the microtubule system, and taxanes are considered microtubule stabilizing 
agents. Thus, a common target of cytotoxic damage is involved. 
However, PTX is not commonly used for IPEC treatment because of side effects (abdominal 
pain and life-threatening hypersensitivity reactions) reported for Taxol®, the initially available 
commercial formulation [14]. Therefore, novel PTX formulations have been developed 
without resorting to toxic excipients to improve the solubility of paclitaxel [15, 16]. Such as, 
Abraxane®, an albumin-bound PTX formulation which is already available on the market for 
the treatment of metastatic breast cancer [17] and Genexol®PM, a polymeric micellar PTX 
formulation, which shows good results for the treatment of breast, lung and pancreatic cancer 
[18]. However, both formulations were not yet evaluated for the treatment of advanced 
ovarian cancer.  
In this study, the effect of hyperthermia in combination with 3 different paclitaxel 
formulations, Abraxane®, Genexol®PM and Taxol®, was evaluated for (H)IPEC for the 
treatment of peritoneal carcinomatosis of ovarian origin. The toxicity (maximum tolerated 
dose, recovery time and bioavailability) and efficacy (tumor growth delay and PTX tumor 
accumulation) of these treatments were evaluated following (H)IPEC.  
MATERIALS AND METHODS 
Materials 
Three commercially available paclitaxel (PTX) formulations were used: Taxol® (1:1 
Cremophor®EL/ethanol mixture) from Bristol-Myers Squibb (Brussels, Belgium), Genexol®PM 
(polymeric-micellar formulation using a biodegradable monomethoxy poly(ethylene glycol)-
block-poly(D,L lactide) block copolymer) from Samyang (Seoul, Korea) and Abraxane® (PTX 
albumin-bound particles) from Abraxis Bioscience (London, UK).  
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In vitro cytotoxicity 
An ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture Collection) 
was cultured at 37 °C in a 5% CO2-containing humidified atmosphere. SKOV-3 cells were 
cultured in McCoys medium (Invitrogen, Merelbeke, Belgium). The medium was 
supplemented with 10% fetal bovine serum, penicillin, streptomycin (Invitrogen, Merelbeke, 
Belgium) and fungizone (Bristol Myers Squibb, Brussels, Belgium).  
The cytotoxicity of the different PTX formulations at different temperatures (37 °C and 41.5 
°C) was tested at PTX concentrations of 0.01, 0.1, 1, 5 and 10 µg/ml, 8 wells per concentration 
were used.  
To evaluate the cytotoxicity, 20x103 cells/ml were seeded in 96-well plates (Sarstedt, Newton 
NC, USA). After 72 hours, 20 µl medium was removed and replaced by the test formulation. 
After incubation for 1 hour both at 37 °C or 41.5 °C (i.e. to mimic the HIPEC procedure used 
during in vivo studies), the medium was entirely removed and replaced by 200 µl fresh 
medium in each well. Afterwards, the cells were incubated for 24 and 96 hours at 37 °C under 
5% CO2-atmosphere. The cytotoxicity of the test formulations was determined via MTT assay 
and compared with the non-treated cells. The MTT procedure is described in Chapter 1. 
Afterwards, the optical density was measured at 570 nm normalizing with a reference 
wavelength of 650 nm using an ELISA-plate reader (Paradigm Detection Platform, Beckman 
Coulter, Suarleé, Belgium). 
(H)IPEC procedure 
Female athymic nude rats (Harlan, Horst, The Netherlands) were kept in standard housing 
conditions with water and food ad libitum and a 12 hours light/dark circle. All animal 
experiments were approved by the institutional review board of the Faculty of Medicine, 
Ghent University (ECD 09/06). 
After anesthetizing each rat with 3% isoflurane (Forene®, Abbott, Waver, Belgium) a vertical 
incision was made along the midline in the abdominal wall muscle. The abdominal wall muscle 
was attached to a metal ring which was placed a few centimeters above the incision. The inlet 
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and outlet tubing (Pumpsil®, Watson-Marlow, Zwijnaarde, Belgium) was placed in the 
peritoneal cavity for perfusion with the cytostatic solution over a period of 45 min. To evaluate 
the influence of the temperature the solution was passed through a heat exchanger set at 37 
°C (IPEC) or 41.5 °C (HIPEC). During perfusion, the perfusate solution and body temperature 
of the rat were closely monitored and data were collected using E-Val® 2.10 Software (ELLAB®, 
Roedovre, Denmark).  
Maximum tolerated dose 
The maximum tolerated dose (MTD) was determined for all PTX formulations at HIPEC settings 
(i.e. 45 min perfusion at 41.5 °C). MTD was defined and determined as described by Bouquet 
et al. [19]. Based on the MTD of Taxol® (0.24 mg/ml) [20], a PTX concentration of 0.21 mg/ml 
was used as starting point. In combination with the MTD, the time to regain their initial body 
weight (recovery time) was also evaluated. The recovery time was evaluated for rats treated 
under normothermic and hyperthermic conditions. The time to regain the initial body weight 
was evaluated with a 2-way ANOVA with a significance level of 0.05 (SPSS 19.0). 
Bioavailability 
Blood was sampled in heparin-containing tubes via a catheter which was placed in the arteria 
carotis. Blood samples were taken at 0, 15, 30, 45, 60 and 90 min after starting the perfusion. 
Perfusate samples were collected at 0, 15, 30 and 45 min after starting perfusion, to ensure 
that an accurate dose was administered during (H)IPEC procedure. After the bioavailability 
study rats were euthanized. Blood samples were immediately centrifuged, and separated 
plasma was stored at -80 °C until analysis.  
The perfusate and plasma samples were analysed as previously described in Chapter 1. 
For the bioavailability study, the pharmacokinetic parameters of the PTX treatment groups 
were compared using a 2-way ANOVA with a significance level of 0.05 (SPSS 19.0). The AUC 
was log-transformed before analysis. 
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Tumor model 
Donor rats were injected with 30x106 SKOV-3 cells between the peritoneum and the 
abdominal muscle to induce a tumor. The animals received a daily subcutaneous injection of 
3 mg cyclosporine over a period from 3 days prior until 10 days after tumor cell injection. After 
3 to 4 weeks, tumor size was sufficiently enlarged to transplant tissue samples (5 x 5 mm, with 
a thickness of 3 mm) on the parietal peritoneum of an acceptor rat. The acceptor rat also 
received daily subcutaneous injection of 3 mg cyclosporine from 3 days prior until 10 days 
after tumor transplantation to ensure tumor attachment. Two weeks after transplantation, 
the tumor had attached to the peritoneum and was sufficiently grown to perform the tumor 
growth delay (TGD) experiment and determine PTX accumulation in the tumor. 
Tumor growth delay study 
The effect of the PTX formulations on tumor growth was evaluated via a Siemens® Trio 3T 
clinical MRI scanner (Erlangen, Germany). Prior to the MRI scan, rats were anaesthetized with 
Rompun 2% (Bayer, Diegem, Belgium) and ketamine 1000 CEVA (Ceva, Amersham, UK) using 
a dose of 10 mg/kg and 90 mg/kg, respectively. The rats were placed prone in a (wrist) coil to 
measure the tumor volume. A T1-weighted 3D FLASH sequence was applied with a flip angle 
of 10°, a repetition time of 13 ms and an echo time of 4.9 ms to obtain a voxel size of 0.19 x 
0.19 x 0.4  mm3. In order to easily locate the tumor, the rat was palpated and a vitamin B12 
pellet was attached to the skin where the tumor was located. Tumor volume was defined by 
creating a volume of interest (VOI) consisting of a stack of planar regions of interest (ROI’s) 
using PMOD software (PMOD Technologies, Adliswil, Switserland). Rats were scanned 1 day 
before (H)IPEC treatment (day 0) to measure the initial volume of the tumor. At day 1 rats 
were treated with PTX formulations. Tumor volume was evaluated 7 and 14 days after (H)IPEC 
treatment to monitor the effect of the formulations. 
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Figure 1. Visual predictive check plots for the different paclitaxel formulations. Groups 0, 1, 2 and 3 
correspond to the non-treated group, Taxol®, Genexol®PM and Abraxane® respectively. Blue circles 
denote observed ln-transformed tumor sizes at different measurement times. Solid black lines indicate 
model predicted median ln-transformed tumor sizes whereas dashed black lines represent model 
predicted 2.5 and 97.5 percentiles. The blue and red areas represent the confidence regions around 
the model predicted 2.5 and 97.5 percentiles and the median respectively.  
For the TGD study, 120 tumor sizes were measured, originating from 42 rats at 3 different 
measurement occasions (day 0, day 7 and day 14), divided in 7 groups (the non-treated group 
and Taxol®, Abraxane®, Genexol®PM, each consisting of a normo- and hyperthermia group). 
The tumor sizes were ln-transformed prior to analysis using a linear mixed effects model. 
Parameter estimates were obtained using LAPLACE estimation method in NONMEM® (Version 
7.2, GloboMax LLC, Hanover, US). 
For the blank group the linear rate of tumor growth as well as the inter-individual variability 
in tumor growth was estimated. For the different formulations, the baseline measurements 
Hyperthermia for intraperitoneal chemotherapy: is there an additional effect in combination with paclitaxel? Ι Chapter 2 
 
 75 
 
as well as the inter-individual variability in the formulation-specific baseline measurements 
were modeled. To accommodate the apparent biphasic effect of the different formulation on 
tumor growth, a piecewise-linear regression model was used. For each formulation a 
parameter was estimated describing the decrease in tumor volume between day 0 and day 7 
and another parameter was estimated to describe the tumor regrowth between day 7 and 
day 14. 
To elucidate the potential interaction between hyperthermia and the PTX formulations, 
additional parameters estimating the difference between formulation effects of the 
normothermic and hyperthermic groups were added to the model. A visual predictive check 
provides evidence of adequate model fit for the data (Fig. 1). 
Paclitaxel tumor penetration 
After rinsing and weighing, samples were suspended in water and tissue was mechanically 
disrupted. Subsequently, internal standard (C13-paclitaxel) was added. Tumor tissue was then 
enzymatically digested using a proteinase-K and a lipase solution (both Sigma-Aldrich, Diegem, 
Belgium). Tissue suspensions were left to incubate overnight at 55 °C whilst continuously 
being shaken (IKA®, Staufen, Germany).  
After centrifugation of the digested tissue suspension at 10.000xg for 20 min, supernatant was 
collected and subjected to solid phase extraction. In short, after loading of the sample, the 
SPE cartridges (Oasis® HLC cartridges, Waters, USA) were washed with a sodium hydroxide 
(pH 10.0) solution and a 70% (v/v) methanol solution in water. Following elution of PTX, 
samples were concentrated by evaporation of methanol under a mild nitrogen stream (30 
min, 35 °C). Finally, after reconstitution, samples were injected onto the Waters Acquity UPLC 
system (BEH C18 column). Paclitaxel and C13-paclitaxel were detected with a Quattro Ultima 
triple quadrupole system (Micromass Waters, Manchester, UK). The measurement range of 
the analytical method was 2.0 – 500 ng/g. Total imprecision and trueness were calculated on 
results of repeated analysis of quality controls and complied with the FDA guidance 
specifications on maximum tolerable bias and imprecision for all QC levels. (Trueness: 93.3 – 
98.0 – 96.5; Imprecision: 20.4 – 3.2 – 1.8; both expressed as %). 
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RESULTS 
In vitro cytotoxicity 
The cytotoxicity of the PTX formulations in combination with or without hyperthermia was 
evaluated on SKOV-3, an ovarian carcinoma cell line. Figure 2 shows no significant differences 
between the formulations at different time points. Although the PTX incubation time was 
short (PTX was removed after 1 hour), the cytotoxic effect (for the highest PTX dose) increased 
in function of time: 81 ± 1%, 71 ± 9% and 68 ± 1% after 24 hours vs. 17 ± 2%, 19 ± 1% and 19 
± 1% after 96 hours for Abraxane®, Taxol® and Genexol®PM respectively, under normothermic 
conditions. Lower PTX concentrations (0.01 – 0.1 µg/ml) gave no reduction of cell viability 
under normothermic conditions, whereas cells treated under hyperthermic conditions 
showed a reduction of cell viability after 96 hours : 76 ± 2%, 72 ± 8% and 64 ± 4% for 
Abraxane®, Taxol® and Genexol®PM, respectively. Adding hyperthermia to higher PTX 
concentrations (1 – 10 µg/ml) showed no additional decrease of cell viability.  
Table I. Toxicity of different paclitaxel formulations after (H)IPEC treatment at normothermic 
and hyperthermic conditions.  
Treatment Days to regain 100% body weight 
Taxol® 
41.5 °C 13.4 ± 1.7 
37 °C 10.2 ± 0.6 
Genexol®PM 
41.5 °C 6.4 ± 0.6 
37 °C 3.8 ± 0.9 
Abraxane® 
41.5 °C 7.8 ± 0.8 
37 °C 6.1 ± 0.5 
 
Evaluation of the toxicity 
The maximum tolerated dose (MTD) of the PTX formulations was determined by monitoring 
the survival rate and body weight of the rats following HIPEC treatment. For Abraxane® and 
Taxol® a PTX concentration of 0.27 mg/ml resulted in mortality, while the PTX concentration 
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could be increased to 0.3 mg/ml before mortality was observed in rats treated with 
Genexol®PM. Hence, 0.24 mg/ml was set as MTD for Abraxane® and Taxol®, and 0.27 mg/ml 
for Genexol®PM. At a PTX dose of 0.24 mg/ml, rats treated with Abraxane® and Genexol®PM 
recovered in approximately one week, while rats treated with Taxol® needed 13.4 ± 1.7 days 
to regain their initial body weight (Table I). These results suggested a lower toxicity for 
Genexol®PM and Abraxane® compared to Taxol® (p=0.00). Moreover, for all formulations, rats 
treated under normothermic conditions recovered significantly faster compared to those 
treated at hyperthermic conditions (p<0.05). 
Since the toxicity of a formulation intended for local intraperitoneal drug administration is 
related to the systemic uptake, the rationale for (H)IPEC is to maximize local PTX 
concentration, thus enhancing drug penetration in tumor tissue while minimizing systemic 
uptake. Maximum plasma concentrations were detected 30 min after starting (H)IPEC for 
Abraxane® and Genexol®PM, and after 60 min for Taxol® both under normothermic and 
hyperthermic conditions. Monitoring of PTX plasma concentrations was limited to a 60 min 
period, since previous research [20] showed no further increase in PTX plasma concentrations 
after removing the cytotoxic solution from the peritoneal cavity (i.e. after 45 min).  
Table II. Geometric pharmacokinetic parameters (± SD) of different paclitaxel formulations 
after (H)IPEC treatment. 
Treatment 
AUCIP, t=45min 
(mg.min/ml) 
AUCPl, t=60min 
(µg.min/ml) 
AUC t=45 min ratio* 
Taxol® 
37 °C 7.0 ± 1.4 2.1 ± 1.1 4995 ± 1539 
41.5 °C 6.5 ± 1.1 2.6 ± 0.8 4940 ± 1945 
Genexol®PM 
37 °C 6.2 ± 0.8 3.5 ± 1.2 3451 ± 805 
41.5 °C 6.5 ± 1.0 4.0 ± 1.6 3355 ± 1099 
Abraxane® 
37 °C 7.2 ± 1.2 11.3 ± 1.5 609 ± 465 
41.5 °C 7.6 ± 1.6 14.7 ± 1.9 829 ± 523 
*area under the curve ratio of intraperitoneal PTX concentration and plasma PTX 
concentration over a period of 45 min 
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Figure 2. Viability of the SKOV-3 cell line after application of different paclitaxel formulations at 
normothermic (37 °C) and hyperthermic (41.5 °C) conditions. (A) Abraxane®,(B) Taxol® and (C) 
Genexol®PM.  
Intraperitoneal perfusion with Taxol® and Genexol®PM resulted in similar, non-significant 
pharmacokinetic profiles, whereas perfusion with Abraxane® yielded higher PTX plasma 
concentrations compared to Taxol® and Genexol®PM (Fig. 3). The different IP clearance of PTX 
was also reflected in the pharmacokinetic parameters (Table II). Two-way ANOVA showed no 
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significant differences of AUCPl, t=60min and Cmax between normo- and hyperthermic conditions 
(p=0.09). In contrast the AUCPl, t=60min of Abraxane® was significantly higher both under 
normothermic and hyperthermic conditions compared to the Taxol® and Genexol®PM groups 
(p=0.00). During (H)IPEC the PTX concentrations in the abdominal cavity were much higher 
than in plasma (Table II) for all PTX formulations, resulting in high AUC ratio’s. The AUC ratio 
of Abraxane® is significantly lower (p<0.05) compared to the other two formulations. As no 
significant differences in AUCIP were observed between the formulations and the 
administered concentration was similar, a higher systemic toxicity would be expected after 
(H)IPEC treatment with Abraxane®. 
 
Figure 3. Paclitaxel plasma concentration (ng/ml) (± SD) in rats (n=6) after HIPEC treatment with a 
paclitaxel concentration of 0.24 mg/ml delivered via (▲) Abraxane®, () Genexol®PM and (●) Taxol® 
under (A) hyperthermic conditions and (B) normothermic conditions. 
Evaluation of the efficacy 
No differences in PTX tumor accumulation were observed between the normothermic and 
hyperthermic groups (p>0.05) (Table III). Also no differences (p>0.05) in PTX concentrations 
were observed between the different PTX treatment groups. In comparison with the plasma 
concentration high PTX concentrations were found in the tumor.  
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Table III. Paclitaxel tumor accumulation (± SD) after (H)IPEC treatment (n=4). 
Treatment PTX tumor concentration (µg/g) 
Taxol®  
37 °C 10.5 ± 5.1 
41.5 °C 8.4 ± 1.7 
Genexol®PM  
37 °C 9.8 ± 3.4 
41.5 °C 10.9 ± 5.5 
Abraxane®  
37 °C 8.3 ± 1.9 
41.5 °C 7.2 ± 1.4 
 
Based on the linear regression model (equation 1), an estimation of the mean tumor growth 
in function of time was made (Fig. 4). For the non-treated group (solid line) tumor volume 
increased in function of the time, while the PTX treated rats showed a significant decrease in 
tumor volume till 7 days after the treatment. As the rats were implanted with a single tumor 
nodule (>0.5 cm) to simplify analysis, the tumor was not completely eradicated by (H)IPEC and 
tumor volume increased again between day 7 and day 14 for all PTX formulations.  
Equation 1. Piecewise-linear regression model to predict tumor volume including the 
hyperthermic effect.  
𝑇𝐼𝑀𝐸 < 7 𝑑𝑎𝑦𝑠: 𝑌𝑖,𝑗,𝑘 =  𝐼𝑛𝑡𝑗,𝑘 + 𝑇𝐼𝑀𝐸𝑖 ∗ 𝛽1,𝑗,𝑘 ∗ 𝐼1,𝑗,𝑘 
𝑇𝐼𝑀𝐸 ≥ 7 𝑑𝑎𝑦𝑠: 𝑌𝑖,𝑗,𝑘 =  𝐼𝑛𝑡𝑗,𝑘 + 𝑇𝐼𝑀𝐸𝑖 ∗ 𝛽1,𝑗,𝑘 ∗ 𝐼1,𝑗,𝑘  + (𝑇𝐼𝑀𝐸𝑖 − 7) ∗ 𝛽2,𝑗,𝑘 ∗ 𝐼2,𝑗,𝑘 
With 𝐼𝑛,𝑗,𝑘 = {
1, 𝐼𝐹 𝑔𝑟𝑜𝑢𝑝 = 𝑁𝑜𝑟𝑚𝑜𝑡ℎ𝑒𝑟𝑚
𝛽𝑛,𝑗,𝑘, 𝐼𝐹 𝑔𝑟𝑜𝑢𝑝 = 𝐻𝑦𝑝𝑒𝑟𝑡ℎ𝑒𝑟𝑚
 
With 𝜀𝑖~𝑒
𝑁(0,𝜎2) 
With: 
I = hyperthermic interaction term, Int = Intercept (mm3), β = Slope (mm3/day) 
i (time) = 0, 7, 14 days  
j (treatment groups) = Placebo, Taxol®, Genexol®PM, Abraxane®    
k (temperature) = 0 (normotherm), 1(hypertherm) 
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Despite the increase of tumor volume at day 14, all formulations had a significant decrease in 
tumor growth compared to the non-treated group which had a tumor volume of 147 ± 12% 
and 257 ± 72% at day 7 and day 14, respectively (Fig. 5). Comparing the different PTX 
formulations showed a significant decrease in tumor volume for the Abraxane®-treated group 
(p=0.0073) between day 0 and 7 compared to the Taxol® and Genexol®PM-treated rats which 
showed a similar evolution of tumor growth (Table IV). To elucidate the potential interaction 
effect of hyperthermia with the PTX formulations, additional parameters estimating the 
relative difference between the formulation effects in the normothermic versus hyperthermic 
groups were added to the model. No significant decrease of tumor volume was observed by 
adding hyperthermia to the therapy as the estimated interaction term was not significantly 
different from 1 (Table IV, gray shaded area).  
 
Figure 4. Model estimated tumor size versus baseline for the different paclitaxel formulations. The 
black solid line represents the placebo group whereas the dashed lines represent model predictions 
for the Taxol® and Genexol®PM-treated rats. The model predictions for the Abraxane® group are 
represented by the black dotted line. 
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Table IV. Parameter estimates of the effects on tumor growth and the additional effect of 
hyperthermia. 
INTERCEPT (Int) (mm3) 
Parameter Estimate SE RSE (%) 95% CI 
Blank 66.9 19.4 29.0 28.88 – 104.92 
NORM Taxol® 62.1 6.15 9.9 49.95 – 74.05 
NORM Genexol®PM 75.2 21.6 28.7 32.86 – 117.54 
NORM Abraxane® 363.0 46.5 12.8 271.86 – 454.14 
HYP Genexol®PM 122.0 22.6 18.5 77.70 – 166.30 
HYP Abraxane® 183.0 80.3 43.9 25.61 – 340.39 
SLOPE (β) (mm3/day) 
Parameter Estimate SE RSE (%) 95% CI 
Blank  (day 0 –> day 14) 6.5 3.0 45.9 -0.65 – 12.37 
Taxol® (day 0 –> day 7) -3.6 0.65 17.9 -4.86 – -2.34 
Genexol®PM (day 0 –> day 7) -3.2 0.95 29.6 -5.09 – -1.35 
Abraxane® (day 0 –> day 7) -9.5 3.6 37.4 -16.46 – -2.54 
Taxol® (day 7 –> day 14) 4.4 1.1 24.9 2.25 – 6.57 
Genexol®PM (day 7 –> day 14) 4.4 1.2 27.6 2.04 – 6.86 
Abraxane® (day 7 –> day 14) 10.3 2.9 27.8 4.69 – 15.90 
HYPERTHERMIC INTERACTION TERM (I)  
Parameter Estimate SE RSE (%) 95% CI 
HYP Taxol® (day 0 –> day 7) 0.95 0.31 32.7 0.34 – 1.56 
HYP Taxol® (day 7 –> day 14) 1.6 0.75 47.7 0.10 – 3.04 
HYP Genexol®PM (day 0 –> day 7) 1.2 0.69 56.6 -0.13 – 2.55 
HYP Genexol®PM (day 7 –> day 14) 0.98 0.73 74.9 -0.46 – 2.41 
HYP Abraxane® (day 0 –> day 7) 1.2 0.30 25.7 0.58 – 1.74  
HYP Abraxane® (day 7 –> day 14) 1.2 0.38 31.6 0.46 – 1.96 
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DISCUSSION 
In many institutions IPEC is performed under hyperthermic conditions as hyperthermia not 
only acts in a cytotoxic way itself but also sensitizes tumor cells to radiotherapy (thermal 
radiosensitization) and various cytostatic drugs (thermal chemosensitization). Hyperthermia 
should also increase the penetration of cytostatic drugs into the tumor. 
Conflicting results have been reported from in vitro and in vivo studies on the combination of 
PTX with hyperthermia [1]. The rationale for the use of hyperthermia with taxanes is based on 
the fact that both interact with the microtubule system. In this study 3 different PTX 
formulations were used in order to exclude the toxic effect of Cremophor®EL present in the 
commercially available formulation Taxol®. Weiszhár et al. [21] identified that the side effects 
following administration of Taxol® are mainly due to the presence of Cremophor®EL. 
Based on the results of the MTT test, no differences in cytotoxic effect were observed between 
the different PTX formulations. On the other hand, hyperthermia has a cytotoxic effect at low 
PTX concentrations but this effect was undone by the strong cytotoxic effect of PTX at higher 
concentrations. Since hyperthermia has no additional or synergetic effect in vitro combined 
with PTX, the hypothesis that hyperthermia would increase the drug entry into the cells [22] 
is not valid for PTX on SKOV-3 cells.  
As (H)IPEC is a promising therapy for the treatment of peritoneal carcinomatosis of ovarian 
origin and PTX is an ideal molecule for (H)IPEC treatment due to its pharmacokinetic profile 
and significant first pass effect, it is important to optimize the PTX treatment protocol. (H)IPEC 
treatment is characterized by high local doses resulting in a high efficacy and a low toxicity. In 
this study, the toxicity was examined by the maximum tolerated dose, the recovery time of 
the rats and the bioavailability of PTX in the plasma, as these concentrations are a prediction 
for the PTX induced side effects such as neutropenia and neuropathy. 
Based on the results of the toxicity studies, Genexol®PM presents a suitable alternative to 
Taxol®, as it has a similar pharmacokinetic profile but a lower toxicity (higher MTD and faster 
recovery compared to Taxol®) considering the absence of the toxic surfactant, Cremophor®EL. 
In contrast to systemic therapy where drug delivery to the tumor cells occurs via the 
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circulation, drug delivery to tumor cells during local therapy depends in the first place on the 
ability of the drug to penetrate the tumor by diffusion through tumor interstitium. The 
recirculation of the drug absorbed from the peritoneal cavity is of lower importance.  
The efficacy of the treatment was analysed by the penetration of PTX in the tumor and by a 
TGD study. While some studies [23, 24] show that hyperthermia increases drug accumulation 
in the tumor, our results showed no significant differences in PTX tumor accumulation 
compared to the normothermic treatment group. Although no differences in PTX tumor 
penetration between the different formulations were observed, Abraxane® showed a higher 
decrease in tumor volume compared to Genexol®PM and Taxol®. This can suggest that the 
increased effect of Abraxane® which also has higher PTX plasma levels, is determined by the 
PTX tumor penetration but also by the recirculation of PTX. As already described, (H)IPEC 
treatment is characterized by high local doses resulting in a high efficacy and a low toxicity. 
Both Abraxane® and Genexol®PM, in a different way, meet these requirements.  
 
Figure 5. Tumor volume (mean ± SD) (%) compared to day 0, measured by MRI 7 days and 14 
days after (H)IPEC treatment (n=6). 
One has to wonder whether the slightly higher effect on tumor growth caused by Abraxane® 
compensates its higher systemic toxicity. In spite of the differences between the different 
treatment groups, all tumor nodules showed a significant volume reduction compared to the 
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non-treated animals. But after treatment, the remaining tumor cells restarted to proliferate 
and after 7 days the tumor size increased again. Due to the limited penetration of anticancer 
drugs, cytostatic drugs only penetrate a few millimeters into the tumor tissue, IP 
chemotherapy is only effective in micrometastases or tumors smaller than 5 mm in diameter 
[25]. However, in clinical practice cytoreductive surgery removes first all visible tumor nodules 
prior to HIPEC treatment which is used to remove all microscopic disease (<0.5 cm) and to 
prevent implantation of tumor cells at the resection site and on other peritoneal surfaces. 
Therefore, one can assume that in practice all remaining microscopic tumors will be removed 
by (H)IPEC treatment. 
Although the direct cytotoxic effect of heat is already known, conflicting results have been 
reported regarding the interaction of heat and taxanes. Debree et al. reviewed studies 
regarding thermal enhancement on PTX therapy [1], where all studies varied in drug 
concentration, exposure time, degree and duration of hyperthermia and cell type. Only two 
studies [26, 27] showed an increased cytotoxic effect when PTX was combined with 
hyperthermia. In our study no enhancement was seen under hyperthermic conditions when 
cancer cells were exposed to a high local PTX concentration. These data indicated that 
hyperthermia is less preferred in intraperitoneal perfusion therapy as it results in a similar 
bioavailability and tumor reduction, but a longer recovery time compared with normothermic 
perfusion. 
CONCLUSION 
Hyperthermia in combination with intraperitoneal perfusion did not present an added value 
as it resulted in a similar efficacy and a higher toxicity (a longer recovery time) compared with 
the normothermic treatment group. Both Abraxane® and Genexol®PM are suitable 
formulations for IPEC treatment of peritoneal carcinomatosis of ovarian origin. Genexol®PM 
meets all requirements for IPEC treatment: administration of high doses with a low systemic 
exposure and a limited toxicity but the TGD study showed a lower decrease in tumor volume 
compared to Abraxane®, which has a higher systemic absorption. To draw any conclusion 
about the best alternative formulation for Taxol® further evaluation of the systemic toxicity 
of Abraxane® is needed. 
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INTRODUCTION 
Little is known about the penetration and distribution of cytotoxic agents within solid tumors. 
After intravenous therapy, the cytotoxic agent must be delivered to the tumor by its imperfect 
blood vasculature, cross vessel walls into the interstitium and penetrate multiple layers of 
solid tissue [1]. When the cytotoxic drug is in direct contact with the tumor, as in regional 
therapy, drug delivery to the tumor cells occurs primarily by diffusion through the interstitial 
space [2]. Intraoperative intraperitoneal chemotherapy (IPEC) is an example of regional 
therapy and is used for the treatment of malignancies which are confined to the abdominal 
cavity such as ovarian, colon and appendiceal cancer [3, 4]. The strong rationale behind this 
therapy has translated into an increased 5-year survival for patients with ovarian cancer [5]. 
The principal idea of IPEC is to expose cancer cells within the abdominal cavity to high local 
drug concentrations, while minimizing the systemic side effects [6]. Although the results for 
IPEC treatment are very promising, there are still many uncertainties about the treatment 
protocol. No standard treatment in terms of schedule, residence time, drug, or carrier solution 
has been established. One of the limiting factors for IPEC is the limited penetration of the 
cytostatic drugs into the tumor [7]. Several studies, for different cytotoxic agents, were 
already performed to determine the penetration profile after intraperitoneal (IP) treatment. 
In spite of the high local concentrations, the direct penetration of these drugs into the tumor 
is limited, ranging from several cell layers to 1 – 3 mm [8]. There is strong evidence that the 
antitumor activity of cytostatic drugs is closely related to the amount of drug reaching the 
tumor, so the limited penetration may limit the antitumor effect, but it may also protect the 
healthy cells on the mucosal side of the gastrointestinal tract. Successful chemotherapy 
induces cell death, including apoptosis, or programmed cell death, which indicates tumor 
response to the therapy [9, 10]. 
In this study, the tumor penetration of paclitaxel (PTX), a highly protein-bound drug, widely 
used for the treatment of breast, lung, and advanced ovarian cancer [11], was evaluated after 
IPEC treatment. PTX has a low water solubility, a high molecular weight and undergoes a 
significant first pass metabolism in the liver [12] which makes it a promising molecule for IP 
treatment because of limited absorption from the peritoneal cavity. The unbound 
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concentration of PTX penetrates into the tumor cells and shows a high affinity with the 
intracellular binding sites. These intracellular concentrations are critical for the cytotoxic 
effect of PTX. The efficacy of the penetration was evaluated by scoring the apoptosis. In a 
second phase, an exploratory study was performed in order to characterize the tumor 
penetration, systemic pharmacokinetics (PK) and pharmacodynamics (PD) of PTX after IPEC 
(by varying the contact time and dose of the treatment). 
MATERIALS AND METHODS 
Materials 
Taxol® (6 mg/ml PTX in a 1:1 Cremophor®EL/ethanol mixture) from Bristol-Myers Squibb 
(Brussels, Belgium) was used as model PTX formulation in order to evaluate the penetration 
of PTX. 
Tumor model 
A human ovarian carcinoma cell line (SKOV-3, obtained from the American Type Culture 
Collection) was cultured at 37 °C in a 5% CO2-containing humidified atmosphere. SKOV-3 cells 
were cultured in McCoys medium (Invitrogen, Merelbeke, Belgium) which was supplemented 
with 10% fetal bovine serum, penicillin, streptomycin (Invitrogen, Merelbeke, Belgium) and 
fungizone (Bristol Myers Squibb, Brussels, Belgium).  
Adult female athymic nude rats (Harlan, Horst, The Netherlands) were kept in standard 
housing conditions with water and food ad libitum and a 12 hours light/dark circle. All animal 
experiments were approved by the Ethical Committee of the Faculty of Medicine, Ghent 
University (ECD 09/06). 
Donor rats were injected with 30x106 SKOV-3 cells in a volume of 0.2 ml between the 
peritoneum and the abdominal muscle to induce a tumor. The animals received a daily 
subcutaneous injection of 3 mg cyclosporine over a period from 3 days prior until 10 days after 
tumor cell injection. After 3 to 4 weeks, tumor size was sufficiently enlarged to transplant 
tissue samples (5 x 5 mm, with a thickness of 3 mm) on the parietal peritoneum of an acceptor 
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rat. The acceptor rat also received daily subcutaneous injections of 3 mg cyclosporine from 3 
days prior until 10 days after tumor transplantation to ensure tumor attachment. 3 weeks 
after transplantation, the tumor was attached to the peritoneum and had sufficiently grown 
to perform the IPEC. 
 
 
Figure 1. Paclitaxel penetration in the tumor after IPEC treatment and harvesting the tumor for the 
paclitaxel penetration study and the apoptotic study. 
IPEC procedure  
After anesthetizing each rat with 3% isoflurane (Forene®, Abbott, Waver, Belgium) a vertical 
incision was made along the midline in the abdominal wall muscle. The abdominal wall muscle 
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was attached to a metal ring which was placed a few centimeters above the incision. The inlet 
and outlet tubing (Pumpsil®, Watson-Marlow, Zwijnaarde, Belgium) was placed in the 
peritoneal cavity for perfusion with the cytostatic Taxol® solution, a PTX dose of 3 mg or 30 
mg was used in a volume of 125 ml 0.9% NaCl. The highest dose was previously determined 
as the maximum tolerated dose in female athymic nude rats [13]. A roller pump (Watson-
Marlow, Zwijnaarde, Belgium) circulated the cytostatic solution through a heat exchanger set 
at 37 °C. During perfusion, the perfusate solution and body temperature of the rat were closely 
monitored and data was collected using E-Val® 2.10 Software (ELLAB®, Roedovre, Denmark). 
IPEC procedure was never performed longer than 45 min and afterwards the abdominal cavity 
was flushed with 0.9% NaCl solution and sutured.  
Tumor harvesting 
To evaluate the PTX tissue concentration and the apoptosis in function of time, the tumor was 
harvested at different time points (5, 15, 30, 45, 60, 90, 120, 240 and 480 min) after starting 
IPEC treatment. After harvesting the tumor, rats were euthanized. A biopsy of the tumor was 
taken in order to obtain cylinder-shaped tumor tissue (± 10 mm in diameter) (Fig. 1). This 
cylinder was divided in two. One half was frozen at -20 °C for PTX analysis, the other half was 
formalin-fixed and paraffin-embedded for cleaved caspase-9 staining. 
Collection of plasma samples 
Blood was sampled in heparin-containing tubes via a catheter that was placed in the arteria 
carotis or arteria femoralis, and blood samples were taken between 5 min and 8 hours after 
starting the perfusion. After sampling, rats were euthanized. Blood samples were immediately 
centrifuged, and separated plasma was stored at -80 °C until analysis. The perfusate and 
plasma samples were analysed as described in Chapter 1. 
For the bioavailability study, the PTX plasma concentrations were log transformed before 
analyses and were compared using a student t-test with a significance level of 0.05 (SPSS 20.0).  
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PTX tissue concentration  
After rinsing and weighing, samples were suspended in water and tissue was mechanically 
disrupted. Subsequently, internal standard (C13-paclitaxel) was added. Tumor tissue was then 
enzymatically digested using a proteinase-K and a lipase solution (both Sigma-Aldrich, Diegem, 
Belgium). Tissue suspensions were left to incubate overnight at 55 °C whilst continuously 
being shaken (IKA® Werke, Staufen, Germany).  
After centrifugation of the digested tissue suspension at 10.000xg for 20 min, supernatant was 
collected and subjected to solid phase extraction. In short, after loading the sample, the SPE 
cartridges (Oasis® HLC cartridges, Waters, Etten-Leur, The Netherlands) were washed with a 
sodium hydroxide (pH 10.0) solution and a 70% (v/v) methanol solution in water. Following 
elution of PTX, samples were concentrated by evaporation of methanol under a mild nitrogen 
stream (30 min, 35 °C). Finally, after reconstitution, samples were injected onto the Waters 
Acquity UPLC system (BEH C18 column). Paclitaxel and C13-paclitaxel were detected with a 
Quattro Ultima triple quadrupole system (Micromass Waters, Manchester, UK). The 
measurement range of the analytical method was 30.0 – 8000.0 pg/mg. 
Given the observed non-linearity in the PTX penetration profile, only 1 side of the tumor was 
used to describe the penetration profile. The data was divided into 2 groups, the first group 
consisted of observations from the ventral part of the tumor, while the second group 
consisted of data from the dorsal part of the tumor. Overlap was allowed between both 
groups for measurements that were obtained in the centre of the tumor. After Ln-
transformation of the measured PTX concentrations, the penetration could be approximated 
by a linear function of depth, using Statistical Analysis Software (SAS). In a second step, an 
elaborate mixed effects model, treating tumor size as a continuous predictor and time of 
measurement as a categorical predictor, was fit to the data. 
Using likelihood-ratio tests (statistical test based on the goodness-of-fit of the model) the 
significance of the different model parameters was evaluated. Parameters that proved to be 
non-significant at the 5% level of significance were removed from the model.  
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Equation 1. Elaborate linear mixed effects model to predict the paclitaxel tumor 
concentration. 
𝐿𝑛(𝐶𝑜𝑛𝑐)𝑖𝑗𝑘 = 𝐼𝑛𝑡 +  𝛽1 ∗ 𝑡𝑖𝑚𝑒𝑖 +  𝛽2 ∗ 𝑠𝑖𝑧𝑒𝑘 + 𝛽3 ∗ 𝐷𝑒𝑝𝑡ℎ𝑗 + 𝛽4 ∗ 𝐷𝑒𝑝𝑡ℎ𝑗 ∗ 𝑡𝑖𝑚𝑒𝑖 + 𝛽5
∗ 𝐷𝑒𝑝𝑡ℎ𝑗 ∗ 𝑠𝑖𝑧𝑒𝑘 + 𝛽6 ∗ 𝑡𝑖𝑚𝑒𝑖 ∗ 𝑠𝑖𝑧𝑒𝑘 + 𝑏𝑘 ∗ 𝐷𝑒𝑝𝑡ℎ𝑗 + 𝜀𝑖𝑗𝑘  
With: 
Int = Intercept, β = slope 
i (time) = 5, 15, 30, 45, 60, 90, 120, 240, 480 min 
j (depth) = 0 – 20 mm     
k = rat specific 
 
Determination of apoptosis by cleaved caspase-9 immunohistochemistry 
Sections of 5 µm thickness were mounted on a rotary microtome (HM® 360, Microm, Walldorf, 
Germany) which were deparaffinized in xylene and rehydrated in a downgraded series of 
ethanol. After washing in PBS, heat-induced antigen retrieval was performed for 30 min in a 
citrate buffer (pH 6), after which the tissue slides were cooled down for 15 min at room 
temperature. The endogenous peroxidase activity was blocked for 15 min with 0.3% hydrogen 
peroxide (DAKO, Glostrup, Denmark). After washing steps, each section was blocked with a 
blocking solution Tris-Buffered saline 0.1% (TBST 5% normal goat serum) for 1 hour at room 
temperature. Primary antibody cleaved caspase-9 (Cell signaling Technology, Leiden, The 
Netherlands, 1/400 in PBST 5%) was incubated overnight at 4 °C. After washing, the tissue 
sections were incubated for 30 min at room temperature with a labeled polymer-horseradish 
peroxidase anti-rabbit secondary antibody (DAKO). The color reaction was developed using 
the chromogen 3,3-diaminobenzidine+ (DAB) for 10 min. After washing, the tissue sections 
were counterstained with Mayer’s haematoxylin for 2 min. TBST 5% normal goat serum was 
used instead of primary antibody as negative control to exclude false-positive responses from 
nonspecific binding of the secondary antibody. 
The number of apoptotic cell fragments present in each tissue section was expressed as a 
fraction of the total number of cells. The apoptotic index was determined by Optronics Color 
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digital camera (Olympus Corporation, Tokyo, Japan) and specialized software (Cell D Olympus 
Imaging Solutions, Münster, Germany). Ten regions of interest (ROI’s) were chosen at random 
at a magnification of 200x. High necrotic regions were excluded from analysis. 
For the apoptosis study, the depth of apoptosis was compared using a one-way ANOVA with 
a significance level of 0.05. The differences between the depth of the apoptosis, the contact 
time and dose were compared using a student t-test with a significance level of 0.05 (SPSS 
20.0). 
RESULTS AND DISCUSSION 
The amount of PTX reaching the tumor nodule is a predictor for the effectiveness of the IPEC 
treatment. To correlate the obtained PTX concentration in the tumor with the cytotoxic effect, 
the apoptotic index (%) was measured by staining cleaved caspase-9 positive cells.  
In a first step, the time course of the cleaved caspase-9 positive cells (Fig. 2) in IPEC-treated 
rats was examined. The rats were treated for 45 min with 30 mg PTX (in 125 ml 0.9% NaCl) 
and the apoptosis was evaluated at different time points. A significant increase in apoptosis 
was achieved between 4 and 36 hours after IPEC treatment. The highest degree of apoptosis 
was obtained 8 hours post-treatment (Fig. 3). 
In all other experiments, the degree of apoptosis will be evaluated between 4 and 8 hours 
after IPEC treatment. To ensure the observed apoptotic effect was due to the use of PTX and 
not to Cremophor®EL, the surfactant used in Taxol®, which has a cytototic effect itself, a 45 
min IPEC treatment was performed with a 2% Cremophor®EL solution (i.e. similar to the 
concentration used in diluted Taxol®). No significant differences in apoptotic effect were 
observed after Cremophor®EL treatment when compared with the non-treated group (Fig. 2). 
To evaluate the PTX distribution in the tumor, PTX concentration was measured in 129 tumor 
slices of 29 rats. The number of tissue slices per rat ranged from 2 to 8. For 20 rats, 
measurements were made per slice, while for 9 rats the whole tumor was analysed. For 
reasons of uniformity all measurements were recalculated to describe the depth of the centre 
of the tumor. Imputation was used to account for the missing observations. For these rats, the 
Paclitaxel tumor penetration after intraperitoneal chemotherapy Ι Chapter 3 
 
  
98  
 
depth of the slices was obtained by assuming that the total size of the tumor equalled the 
mean size for tumors with the same number of slices harvested. The impact of these imputed 
values on the model parameter, will be assessed once the final model is established. Figure 4 
shows the measured PTX concentrations as a function of the depth of penetration. The 
subjects in whom depth measurements were obtained through imputation are depicted via 
red continuous lines in the spaghetti plots. Figure 4 clearly shows that the measured PTX 
concentrations are low in the core of the tumor and higher at the exterior of the tumor 
(ventral and dorsal side of the tumor).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Cleaved caspase-9 immunostaining (x200 original magnification) of tumor specimens in the 
control group (A), and 1 hour (B), 4 hours (C), 8 hours (D), 48 hours after IPEC treatment with Taxol® 
(E) and 8 hours after IPEC treatment with 2% Cremophor®EL (F). Cells stained brown were positive for 
cleaved caspase-9 immunostaining. 
A B 
C D 
E F 
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Figure 3. Time course of the cleaved caspase-9-positive cells (%) (± SD). IPEC treatment of 45 min with 
Taxol® (30 mg PTX). 
The PTX concentration gradually decrease in function of depth, high PTX concentrations were 
observed up to 4 mm into the tumor (Fig. 5). Noteworthy is the fact that although one side of 
the tumor is connected to the abdominal wall, the PTX penetration at that side is similar to 
the PTX penetration at the side embedded in the abdominal cavity which is possibly due to 
the small connection between the tumor and the abdominal wall. No significant differences 
were observed in penetration depth between the dorsal and ventral side of the tumor. Which 
suggests that the PTX penetration is independent of the orientation of the tumor in the 
abdominal cavity. The PTX concentration is layer by layer uniformly distributed to the centre 
of the tumor. The size of the tumor does not influence the PTX penetration profile, as no 
significant differences were observed between the penetration profiles of tumors with 
different sizes (p=0.080). As in clinical practice visible tumors are removed by CRS, a PTX 
penetration of 4 mm will suffice to penetrate the complete residual tumor. The apoptosis 
study showed similar results as the degree of apoptosis is significantly higher in the outer 
layers of the tumor (0 – 4 mm) compared to the centre. Also no significant differences were 
observed between the apoptotic index of the ventral and dorsal tumor side (Fig. 6). The degree 
of apoptosis in the centre of the tumor is significantly higher than the baseline apoptotic signal 
(1.27% ± 0.06%) in untreated tumors confirming PTX penetration in the centre of the tumor. 
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Figure 4. Spaghetti plot measured PTX concentrations as a function of the depth of excised tumor slice 
per rat. The red lines denote subjects for whom no size measurements were available and depth values 
were obtained through imputation. 
The amount of PTX showing up in the tumor nodule is as much governed by non-
pharmacokinetic variables (tumor nodule size, cell density, vascularity and interstitial fluid 
pressure) as by pharmacokinetic parameters (dose, duration, volume and carrier solution) 
[14]. On the basis of PTX tumor penetration, PTX plasma concentrations and the apoptotic 
index, an exploratory study was performed in order to characterize the tumor penetration, 
systemic pharmacokinetics (PK) and pharmacodynamics (PD) of PTX after IPEC. 
The influence of the contact time on the PTX penetration profile was evaluated by removing 
the tumor at different time points. Unexpectedly, no increase in PTX concentrations was 
observed in the tumor by increasing the contact time. Nor were there differences observed in 
the PTX penetration profile. The PTX concentration remains unchanged between 5 min of 
treatment (first time point observed in the study) up to several hours post-treatment (Fig. 7A) 
indicating a saturable paclitaxel tumor penetration.  
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Figure 5. Scatterplots of observed paclitaxel concentrations as a function of penetration depth. The 
open circles depict the observations while the lines depict model predictions.  
As the cytotoxic effect of PTX is related to the obtained concentration, it would be expected 
that the apoptotic index showed similar results after 15 min or 45 min of IPEC treatment. In 
contrast to this theory significant differences (p=0.00) in degree of apoptosis (6 ± 1% vs 12 ± 
4%) were observed in the outer layers of the tumor (0 – 4 mm). A longer contact time resulted 
in similar intratumoral PTX concentrations but in an increased apoptotic effect (Fig. 8A). This 
may be explained by the fact that the efficacy of the drug ultimately depends on the 
intracellular concentrations. As both the intracellular and extracellular concentrations were 
measured, it is possible that the intracellular concentration is increasing by increasing the 
contact time. Although Jordan et al. (1996) described that for high extracellular concentrations 
(>0.001 mM), 30 mg PTX is equal to 0.28 mM, the saturation of the intracellular binding sites 
occurs almost readily in monolayer cultures [15-17]. In clinical practice, perfusions are 
performed from 30 min to 2 hours, on the basis of the developed PK-PD model (work in 
progress), it should be possible to predict the outcome of the increased treatment period.  
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Figure 6. Measured apoptotic index (%) (± SD) as a function of tumor depth after IPEC treatment of 
45 min with Taxol® (30 mg PTX). 
The second analysed pharmacokinetic parameter was the effect of the dose on the PTX tumor 
and plasma concentrations. A dose of 3 mg PTX was compared to 30 mg PTX (i.e the MTD). 
The doses were used in a concentration of 0.024 mg/ml or 0.24 mg/ml. Although the 
concentration of the lower dose was 10-times lower than the MTD, the total PTX tumor 
concentration was similar compared to the high dose treatment (Fig. 7B).  
 
Figure 7. Paclitaxel tumor concentrations (µg/g) (± SD) in rats (n=3) after IPEC treatment with a 
paclitaxel dose of (●) 30 mg and (○) 3 mg in function of the time. (A) shows the PTX tumor 
concentration in function of time over a period of 8 hours, (B) focuses on the first 2 hours. 
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Also no differences were observed in the PTX tumor penetration profile compared to the used 
higher dose. Post-IPEC PTX tumor concentrations were not measured after low dose 
treatment. The apoptotic index was significantly lower (p=0.03) after low dose treatment (Fig. 
8B) compared to the high dose treatment.  
 
Figure 8. Apoptotic index (%) after IPEC treatment with variation in contact time (A), and variation in 
dose (B). 
As well as the PTX tumor penetration, the PTX plasma concentrations were evaluated. The PTX 
plasma levels were much lower compared to the PTX tumor concentrations due to the 
presence of the peritoneal-plasma barrier. In contrast to the tumor concentrations, plasma 
concentrations are no value for the efficacy but are responsible for the systemic toxicity. Here, 
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differences between the low and high dose were observed (Fig. 9). Near the end of the IPEC 
treatment (i.e. 45 min after starting the procedure) the PTX plasma profiles are similar. The 
PTX plasma concentration is still increasing after removing the high dose perfusate, while after 
low dose treatment, the PTX plasma concentration immediately starts decreasing to lower 
concentrations. IPEC therapy with low dose PTX shows both an absorption and elimination 
phase, a Cmax of 67 ng/ml was observed 45 min after starting the perfusion and a T1/2 of 2 hours 
and 40 min was observed. The absorption after high dose perfusion gradually increased till 4 
hours after starting the treatment. This suggests that the hydrophobic PTX might be stored in 
the other tissues, from which PTX is released after removing the chemotherapeutic liquid. 
 
Figure 9. Paclitaxel plasma concentration (ng/ml) (± SD) in rats (n=3) after IPEC treatment (i.e. 45 min) 
with a PTX dose of (●) 30 mg and () 3 mg.  
CONCLUSION 
This study successfully illustrates how PTX is distributed in the tumor. In our xenograft tumor 
model, a PTX tumor penetration was observed independent of the size and the orientation of 
the tumor. Pharmacokinetic parameters as dose and contact time have an influence on the 
efficacy of the IPEC treatment but further research is necessary to get a complete picture of 
this process. 
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INTRODUCTION 
For a long time, peritoneal carcinomatosis (PC) was considered a terminal condition. It is 
demonstrated that a complete cytoreductive surgery (CRS) to remove the macroscopic 
disease in combination with intraoperative intraperitoneal chemotherapy (IPEC) to eradicate 
microscopic residues enhances the overall survival of patients with PC [1]. Intraperitoneal 
chemotherapy needs to be performed immediately after surgery, to ensure that residual 
tumor cells do not get trapped in the postoperative fibrin adhesions [2]. The use of IPEC has 
been reported for PC from colorectal cancer (CRC), ovarian cancer (OC), pseudomyxoma 
peritonei (PMP), and malignant peritoneal mesothelioma [3]. The rationale for IP 
chemotherapy is based on the existence of a peritoneal-plasma barrier, which allows the 
usage of high local doses while limiting systemic drug exposure [4]. While high doses can be 
used, the limiting factor for IPEC treatment is the penetration of the cytotoxic drugs into the 
tumor tissue which is limited to only a few millimetres [5].  
In contrast to the previous chapters PTX was not used as chemotherapeutic agent. In this 
clinical trial, oxaliplatin is used, as in our institution oxaliplatin is most commonly used for 
(H)IPEC treatment. Oxaliplatin, a diaminocyclohexane-platinum compound, which acts as an 
alkylating agent creating DNA adducts leading to apoptosis and impaired cell replication, is 
active against a variety of tumors such as CRC and OC [6]. In ovarian cancer, several large 
randomized trials have demonstrated a statistically significant survival increase associated 
with adjuvant IP platinum-based chemotherapy after primary CRS [7]. 
Although IPEC treatment under hyperthermic conditions (>41 °C) (HIPEC) is already performed 
in many institutions for many years, the additional effect of hyperthermia remains unclear and 
several conflicting results were published. Recently, it was shown that hyperthermia 
potentiates the local absorption of oxaliplatin in Sprague-Dawley rats and that hyperthermia 
would limit its systemic absorption [8]. On the other hand, hyperthermia also induces 
apoptosis in healthy cells which affects the healing of anastomosis [9]. Furthermore, Klaver et 
al. demonstrated no increase in survival rate using hyperthermia compared to normothermic 
treatement [10]. To our knowledge, a clinical benefit from hyperthermia combined with 
chemotherapy compared to chemotherapy alone was never demonstrated.  
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As is the case with the perfusion temperature, the duration of chemoperfusion has not yet 
been standardized. In literature perfusion times range from 30 min to 2 hours [11, 12]. The 
required perfusion time for oxaliplatin would be shorter compared to cisplatin or mitomycin-
C which makes it more practical for clinical use [13]. However in vitro studies have shown that 
by increasing the contact time, the amount of cell death also increases [14]. In literature, the 
use of high dose oxaliplatin (460 mg/m2) was first introduced for HIPEC for the treatment of 
PC of CRC [11]. Although the results are promising for high dose treatment, at the moment a 
variety of doses are used ranging from 200 mg/m2 to 460 mg/m2 [12]. 
In this study, two aspects of IPEC treatment were analysed. First, as the use of hyperthermia 
remains unclear, the use of hyperthermia in combination with oxaliplatin was compared to an 
oxaliplatin treatment alone in order to evaluate the possible synergistic effect of using 
hyperthermia. Second, the pharmacokinetic effect of varying the dose and perfusion time was 
evaluated by increasing the oxaliplatin dose from 200 mg/m2 to 460 mg/m2 while the 
perfusion time was decreased from 90 min to 30 min.  
MATERIALS AND METHODS 
Patient Selection 
Data were obtained from 38 patients who were treated from May 2012 to March 2013 for 
primary or recurrent peritoneal carcinomatosis with cytoreductive surgery and (H)IPEC with 
oxaliplatin. Demographic data are illustrated in Table I. Written informed consent for (H)IPEC 
treatment was obtained prior to treatment, and approval of the study protocol was obtained 
from the institutional review board. 
Chemoperfusion protocol 
Surgery consisted of a combination of organ resection and peritonectomy procedures. Small 
bowel and ileocolic anastomoses were created before, and colonic anastomoses after the 
chemoperfusion. At the completion of the surgery, intravenous folate (20 mg/m2) followed by 
5-FU (400 mg/m2) were administered to the non-ovarian cancer patients. Chemoperfusion 
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was performed using the open abdomen (coliseum) technique. Two Tenckhoff peritoneal 
catheters (Tyco Healthcare, Mechelen, Belgium) for infusion and three Jackson-Pratt drains 
(Cardinal Health Care, Dublin, Ohio, USA) for drainage were placed through the abdominal 
wall. Temperature probes were placed in the pelvis and left and right upper abdomen. The 
extracorporeal circuit consisted of a cardiotomy reservoir (Sorin Group, Mirandola, Italy), a 
CSC14 cardioplegia heat exchanger (Sorin Group, Mirandola, Italy), and a roller pump (COBE 
Cardiovascular, Denver, Colorado, USA). Upon completion of the circuit, a flow of 
approximately 1 L/min was instituted and the abdominal cavity was further heated to 37 °C or 
41 °C depending on the treatment protocol.  
Table I. Demographic details of (H)IPEC-treated patients with oxaliplatin. 
 Group 1 Group 2 Group 3 
Treatment parameters    
     Dose 200 mg 460 mg 460 mg 
     Temperature 37 °C 37 °C 41 °C 
     Time 90 min 30 min 30 min 
N 24 7 7 
Age (years) 54.7 ± 14.2 53.0 ± 16.1 56.9 ± 8.3 
Male (%) 25 14 28 
Female (%) 75 86 72 
Indication    
Colon cancer 7 7 4 
Ovarian cancer 9 - 2 
Neuroendocrine cancer 4 - - 
Gastric cancer 3 - - 
Other 1 - 1 
 
Once the target temperature was reached, oxaliplatin (200 mg/m2 or 460 mg/m2) was added 
to the dextrose 5% solution (2 L/m2) and circulated for 90 min or 30 min, respectively. Body 
surface area was calculated as the square root of (Weight (kg)*Length (cm))/3600). The 
patients were divided in three treatment groups: group 1 was treated at 37 °C for 90 min with 
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a dose of 200 mg/m2 oxaliplatin, group 2 received a treatment at 37 °C for 30 min with a dose 
of 460 mg/m2 and group 3 was treated at 41 °C for 30 min with a dose of 460 mg/m2 
oxaliplatin. Intra-abdominal temperatures were recorded before the start and every 5 min 
during chemoperfusion. The abdominal cavity was not rinsed with saline after the 
chemoperfusion procedure. 
Sample collection 
Blood and perfusion samples were collected during the chemoperfusion. For both 30 min and 
90 min treatments perfusate and blood samples were taken just before starting the procedure 
and 1, 5, 10, 15, 20 and 30 min after starting the treatment. For the 90 min treatment, after 
30 min, blood and perfusate samples were collected every 15 min till the end of the IPEC 
procedure. Postoperative blood samples were collected 2, 4, 8, 12, 24, 36 and 48 hours and 4 
and 7 days after starting the treatment. Samples were kept at -20 °C until analysis by 
inductively coupled plasma-mass spectrometry (ICP-MS). 
Tissue samples of the abdominal wall were collected after removing the cytotoxic agent from 
the abdominal cavity. Tissue samples were formalin fixed and paraffin embedded. Sections of 
20 µm thickness were mounted on a rotary microtome (HM® 360, Microm, Walldorf, 
Germany) and kept on microscopic slides till analysis by laser ablation-inductively coupled 
plasma-mass spectrometry (LA-ICP-MS). 
Data collection 
Postoperatively, the following parameters were collected: mortality (within 30 days or during 
hospital stay), major morbidity (defined as any undesired outcome, leading to prolonged 
hospital stay and/or reoperation), anastomotic leakage, major bleeding, reoperation rate, 
time to remove the nasogastric (NG) tube, duration of the hospital stay and grade 1 to 4 
leukopenia and thrombopenia.  
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Platinum determination in blood and perfusate 
Platinum (Pt) concentrations in blood and perfusate samples were determined using an 
Xseries 2 quadrupole-based inductively coupled plasma mass spectrometry (ICP-MS) 
instrument (Thermo- Scientific, Bremen, Germany). Sample introduction was accomplished 
via a concentric glass nebulizer mounted onto a Peltier-cooled conical spray chamber with 
impact bead. The peristaltic pump delivered the sample at a flow rate of 500 μl/min. A Cetac 
500 autosampler (Cetac, Omaha, NE, USA) was deployed for automatic sample introduction. 
All the isotopes of Pt were monitored, along with the major isotope of thallium (205Tl). The 
instrument was operated at an RF power of 1.400 W. The nebulizer gas (argon) flow rate was 
maintained at 0.85 L/min. Five replicate measurements were performed for every sample and 
standard solution. Calibration solutions containing 0.25, 0.5, 1, 5, 10, 15, and 20 ng/g Pt were 
prepared and analysed. Correlation coefficients for the linear regression lines were always 
higher than 0.99. 
Platinum determination in tissue samples 
Tissue samples were analysed with laser ablation-inductively coupled plasma-mass 
spectrometry (LA-ICP-MS). A New Wave Research UP193HE ArF* excimer-based laser ablation 
system (New Wave Research, Fremont, USA) coupled to an Element XR (Thermo Scientific, 
Germany) double-focusing sector field ICP-MS instrument was used to determine the 
distribution of Pt within the tissue sections. This LA-unit was equipped with a standard circular 
ablation cell with a diameter of 5 cm. 
The area of interest was scanned with a laser beam with a diameter of 70 µm. The scanning 
parameters were selected such as to provide square pixels in the final elemental map [15]. 
The material released from the surface of the sample upon ablation was transported using 
helium as a carrier gas into the ICP ion source. Post-ablation, the helium flow carrying the dry 
sample aerosol was admixed with argon prior to introduction into the ICP. Both laser beam 
diameter and laser repetition frequency have been selected carefully, taking the nature of the 
sample and the concentration of the target element into account. Also the incident laser 
fluence has been optimized. The settings used for the LA-ICP-MS experiments are summarized 
in Table II. 
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Table II. Instrument settings and data acquisition parameters for LA-ICP-MS measurements. 
Laser ablation New Wave Research 
Type 
UP193HE 
ArF* excimer based laser 
Measurements Mapping 
Wavelength (nm) 193 
Lateral scanning speed (µm/sec) 80 
Repetition frequency (Hz) 10 
Laser energy (J/cm2) 0.7-0.8 
Diameter of laser beam (µm) 70 
Ablation chamber Standard cell 
ICP-SFMS Element XR 
Mass resolution (m/Δm) 300 
RF power (W) 850 
Carrier gas flow rate  (L/min) Helium, 0.5 
Make up gas flow rate (L/min) Argon, 0.7 
Number of runs 200-300 
Number of passes 1 
Time per pass (sec) 1 
 
The obtained images were analysed by the NIH ImageJ software (version 1.39s, available from 
http://rsb.info.nih.gov/ij), the blue/green and red coloured pixels were counted and were 
presented as a fraction of the total amount of pixels of the image. 
Statistics 
Differences in the variables with a normal distribution were analysed with an unpaired student 
t-test, non-normally distributed variables were log-transformed before analysis. Statistical 
significance was assumed when p ≤ 0.05. Data analysis was performed by means of SPSS 20.0.  
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RESULTS AND DISCUSSION 
Although pharmacokinetics of oxaliplatin after IPEC treatment have been previously reported 
[16, 17], this study is unique as 2 different parameters for IPEC treatment were evaluated. On 
the one hand the influence of hyperthermia (41 °C) was evaluated during IPEC. It is known 
that hyperthermia has no influence on surgical outcome [18], but in a clinical setting, the 
influence of hyperthermia on pharmacokinetics and morbidity had yet not been investigated. 
On the other hand, the influence of dose and perfusion time on the pharmacokinetic 
parameters was compared using a high dose short treatment (460 mg/m2 for 30 min) or a low 
dose long treatment (200 mg/m2 for 90 min). It is not clear whether the dose or the perfusion 
time has the highest influence on oxaliplatin pharmacokinetics as 460 mg/m2 for 30 min is the 
maximum tolerated dose in patients [11], while other studies have shown that treating cancer 
cells with oxaliplatin for 2 hours resulted in a twofold increase in cell death compared to a 30 
min treatment [14].  
 
Figure 1. Mean (± SD) observed peritoneal platinum concentrations (initial dose=100%) for the 
different treatment groups. 
First the influence of the 3 different treatment modalities on the Pt concentration in the 
perfusate in function of time was evaluated (Fig. 1). In the 3 groups, the Pt perfusate 
concentration decreased in function of time and no significant differences were observed 
between the different treatment groups, indicating that the percentual decrease of the Pt 
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concentration in the perfusate is independent of the treatment temperature or initial 
oxaliplatin dose. In literature, the half-life of Pt in the perfusate was between 18 and 42 min 
after starting the IPEC procedure [16, 17]. In our study, half of the administered dose was 
absorbed between 22 min and 72 min with a mean half-life of 57 min. 
Influence of the temperature 
In this part of the study, a selection bias should be taken in account, as the groups were not 
randomized and patients with the highest PCI score were automatically assigned to the 
hyperthermic treatment group. Comparing the mean Pt blood values and pharmacokinetic 
parameters (Table III), no significant differences were observed comparing the normothermic 
and hyperthermic-treated groups (Fig. 2). The peritoneal fluid to plasma AUC ratio is an 
important factor for the effectiveness of the IPEC treatment [19]. As no differences in Pt blood 
levels and Pt perfusate levels between the treatment groups were observed, the AUC ratio did 
not differ significantly (Fig. 3). When analysing the mean Pt blood values and pharmacokinetic 
parameters, high variances were observed in the hyperthermic-treated group (n=7). 
 
Figure 2. Platinum blood concentrations (µg/g) (± SD) in function of time over a period of 7 days in 
patients of (●) group 3 and () group 2. 
Not all patients in this group depending on the extent of their disease received a complete 
CRS. These incurable patients received a hyperthermic oxaliplatin treatment as (semi-) 
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palliative treatment as it is known that hyperthermia has a cytotoxic effect by itself and it 
would increase drug penetration in solid tumors thereby increasing the cytotoxic efficiency 
[10, 20]. Next to these direct cytotoxic effects, hyperthermia would also enhance the 
antitumor effect of several cytostatic agents by increasing tumor blood supply and 
oxygenation [21].  
Table III. Geometric pharmacokinetic parameters (± SD) of the different treatment modalities 
used during (H)IPEC. 
Treatment groups 
AUCIP t=30min 
(µg.h/g) 
AUCBl t=7days 
(µg.h/g) 
AUC t=30min ratio* 
(mean value) 
Cmax 
(µg/g) 
Group 1 12.2 ± 0.9 111.4 ± 15.2 20.6 2.3 ± 0.6 
Group 2 34.3 ± 4.3 129.6 ± 15.6 28.9 3.8 ± 0.9 
Group 3 29.9 ± 8.2 158.0 ± 70.9 25.1 5.1 ± 2.4 
*area-under-the-curve ratio of perfusate Pt concentration (AUCIP) and blood Pt concentration 
(AUCBl) over a period of 30 min 
Although cytoreduction in hyperthermic-treated patients was less extensive compared to the 
normothermic-treated group more complications were observed in this group (Table IV). From 
the 7 patients treated with hyperthermia, 2 patients showed major bleeding after surgery, 1 
patient had anastomotic leakage and 3 patients went back for surgery while none of the 
patients from the normothermic group showed these complications.  
The World Health Organization (WHO) grading system classifies leukopenia and thrombopenia 
during chemotherapy as follows: absence (grade 0), mild (grade 1-2) and severe (grade 3-4). 
In the hyperthermic group (Group 3) 1 patient showed grade 3 leukopenia and 2 patients were 
diagnosed with thrombopenia (1 patient showed grade 1 and another grade 4 thrombopenia), 
while no patients in the normothermic group showed any bone marrow depression. Although 
both groups are small, these complications indicated a higher toxicity rate for the 
hyperthermic-treated group (Table IV).  
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Figure 3. Platinum concentration (µg/g) (± SD) in (●) blood and () perfusate after IPEC treatment. (A) 
group 1, (B) group 2 and (C) group 3. 
Although the penetration in healthy tissue is different compared to the penetration in tumor 
tissue due to its irregular cell structure and leaky blood vessels, the Pt penetration in healthy 
tissue is here a model for the penetration in tumor tissue. The Pt penetration in healthy tissue 
(abdominal muscle) was analysed as removing of all visible tumor tissue during CRS was 
preferred for the well-being of the patients. Figure 4 shows the results of the Pt penetration 
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through the abdominal muscle. The colours on the images represent the amount of Pt in the 
tissue, ranging from purple indicating very low concentrations over blue and green to red for 
very high Pt concentrations. Higher Pt concentrations were observed at the edge of the tissue 
in the hyperthermic-treated group, shown by the green coloured region (Fig. 4B). 
 
 
 
 
 
 
Figure 4. Platinum tissue penetration evaluated by LA-ICP-MS. (A) group 2, (B) group 3 (white arrow 
indicates the penetration side). 
When analysing the complete tissue sample for the blue and green regions, no differences 
were observed. 29.3 ± 11.4% and 24.8 ± 13.2% of the pictures for the hyperthermic and 
normothermic-treated group, respectively, are coloured green or blue suggesting a similar 
overall Pt penetration. As the Pt concentration is slightly higher at the penetration side after 
HIPEC treatment, while centrally the Pt concentrations are similar, these images indicated that 
hyperthermia is not enhancing the Pt penetration and does not affect penetration depth. 
Thus, normothermic treatment resulted in a similar efficacy and a lower toxicity, which makes 
it a preferable treatment strategy considering the above mentioned complications with 
hyperthermic treatment.  
Influence of the dose and perfusion time 
The dose and perfusion time were evaluated with respect to their influence on oxaliplatin 
pharmacokinetics. Patients were divided in 2 groups: low dose long treatment (200 mg/m2 for 
90 min, group 1) and high dose short treatment (460 mg/m2 for 30 min, group 2). Both groups 
A B 
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were treated under normothermic (37 °C) conditions. When comparing the Pt blood levels of 
both groups (Fig. 5) a significantly higher Cmax (p=0.006) was observed for the patients treated 
with 460 mg/m2 oxaliplatin. Nevertheless, the observed Cmax in group 2 was lower compared 
to the observed values in literature after 2 hours intravenous infusion with clinically used 
doses of oxaliplatin whereby an acceptable systemic toxicity was determined [17]. 
 
Figure 5. Platinum blood concentrations (µg/g) (± SD) in patients in function of time over a period of 
7 days of (●) group 2 and () group 1.  
In our study none of the patients of group 2 developed clinically important bone marrow 
depletion nor were any surgical complications observed (Table IV). Cmax was reached 60 min 
and 30 min after starting the IPEC treatment, for group 1 and group 2 respectively. Although 
the perfusion in group 1 was performed during 90 min, the Pt blood concentrations already 
decreased before the end of the chemoperfusion, indicating that the Pt clearance is higher 
than the Pt absorption. These results can be related to the half-life of Pt in the perfusate (57 
min). These findings would support a decrease of the perfusion time from 90 min to 60 min 
for IPEC treatment with 200 mg/m2 oxaliplatin. In spite of the high Cmax of group 2, the Pt blood 
levels decreased rapidly between 30 min and 60 min after starting the treatment, yielding the 
same blood concentrations as group 1 after 60 min. From that point on, the Pt clearance of 
both groups is similar (Fig. 5).  
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Regardless of the differences in the maximal concentration, no significant differences were 
observed for the AUCBL, t=7days (Table III). The AUC ratio for group 2 is significantly higher 
compared to the AUC ratio of group 1 (Table II), indicating that high Pt concentrations are 
delivered to the area of interest while the systemic toxicity is remains low. 
Table IV. Observed complications after (H)IPEC treatment with oxaliplatin. 
 Group 1 Group 2 Group 3 
Surgery duration (h) 9.6 ± 2.6 8.6 ± 3.0 6.7 ± 3.1 
Mortality 1 0 0 
Major morbidity (%) 16.7 14.3 42.8 
NG drainage (days) 5 (4 – 7.5) 6 (4 – 6) 4 (2.2 – 10.5) 
Hospital stay (days) 14 (12 – 17) 12 (11 – 16.7) 13 (10.2 – 27.7) 
Reoperation rate (%) 12.5 0 42.8 
Major bleeding (%) 0 0 28.6 
Anastomotic leak (%) 12.5 0 14.3 
Leukopenia    
Grade 1 2 0 0 
Grade 2 3 0 0 
Grade 3 2 0 1 
Grade 4 0 0 0 
Thrombopenia    
Grade 1 5 0 1 
Grade 2 1 0 0 
Grade 3 0 0 0 
Grade 4 0 0 1 
 
These results were confirmed by the Pt tissue penetration study. Figure 6 clearly shows a 
significant difference between the Pt penetration of group 2 compared to group 1. Although 
the duration of the perfusion was 3-times higher, very low Pt concentrations were observed 
in patients treated with 200 mg/m2. Only 2.7 ± 2.6% of the tissue coloured blue or green, while 
for the patients treated with 460 mg/m2 for 30 min, 24.8 ± 13.2% of the tissue showed Pt 
penetration. Increasing the perfusion time did not result in a cumulative drug uptake. Most of 
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the cytotoxic drugs have a steep dose-effect curve [22] meaning that the cytotoxic effect is 
related to the delivered Pt concentration. Lower concentrations resulted in a lower cytotoxic 
effect. Based on these results, it can be concluded that the dose is an important factor for the 
Pt penetration while the contact time is of less importance.  
 
 
 
 
 
Figure 6. Platinum tissue penetration evaluated by LA-ICP-MS. (A) Group 2, (B) group 1 (white arrow 
indicates the penetration side). 
CONCLUSION 
As no additional effect of hyperthermia and a dose-related platinum penetration was 
observed, a high dose (460 mg/m2) short normothermic treatment is preferable for IPEC 
treatment of peritoneal carcinomatosis from different origin. 
A B 
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GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
The main objective of this project was to evaluate different paclitaxel (PTX) formulations and 
different treatment modalities for intraperitoneal chemotherapy (IPEC) of peritoneal 
carcinomatosis of ovarian origin. 
In a first step, we were able to develop a stable PTX nanocrystalline suspension containing PTX 
and Pluronic®F-127 in a ratio (w/w) of 4/1 by the wet milling technique. During this thesis, we 
have proven that all evaluated formulations (PTX nanocrystalline suspension, Abraxane®, 
Genexol®PM and Taxol®) were suitable for IPEC treatment. However, differences were 
detected in the toxicity of the different formulations. Although PTX tumor concentrations 
were similar for all formulations, Abraxane® had a higher efficacy compared to the other 
formulations, probably due to more recirculation of PTX to the tumor via the blood flow as 
higher PTX plasma concentrations were detected after Abraxane® treatment. As a low 
systemic exposure is preferred after IPEC treatment (i.e. resulting in a low toxicity) 
Genexol®PM, a biodegradable monomethoxy poly(ethylene glycol)-block-poly(D,L lactide) 
block copolymer, seems the most promising formulation for IPEC use. 
During this project, we were able to map the penetration profile of PTX into a solid tumor. It 
was demonstrated that high PTX concentrations were found up to 4 mm inside the tumor, 
independent of the size and the orientation of the tumor in the abdominal cavity. Moreover, 
the PTX concentration was cell layer by cell layer uniformly distributed to the centre of the 
tumor.  
The evaluation of different parameters (perfusion temperature, perfusion time and dose) 
yielded interesting findings: while in several institutions IPEC is performed under hypertermic 
conditions (>41°C), this work showed (via an experimental study with PTX and a clinical trial 
with oxaliplatin) that there is no clinical evidence that hyperthermia increases the outcome of 
the therapy: hyperthermia resulted in a similar efficacy and a higher toxicity compared to 
normothermic treatment (37 °C).  
 General Conclusions and Future Perspectives 
 
  
128  
 
The clinical trial with oxaliplatin clearly showed that treating the patients with the maximum 
tolerated dose (460 mg/m2) for a short period (30 min) had a similar toxicity compared to a 
low dose treatment (200 mg/m2 for 90 min) in combination with a higher efficacy. The 
experimental study with PTX showed that reducing the exposure time from 45 min to 15 min 
had no influence on the penetrated PTX concentration, whereas it resulted in a lower efficacy 
based on the degree of apoptosis. Decreasing the PTX concentration from the maximum 
tolerated dose to a 10-fold lower dose had no influence on the PTX tumor concentration, while 
a lower degree of apoptosis was observed. The results obtained when varying the PTX dose 
and contact time indicated that PTX uptake in the tumor is saturable and occurs very fast. 
However, further research is required to elucidate the dose-effect relationship of PTX after 
IPEC treatment. 
We can expect that IPEC for the treatment of peritoneal carcinomatosis becomes the new 
standard of care, however unresolved issues remain. In this study just a few parameters of the 
IPEC process were evaluated. Despite the extensive use of IPEC for ovarian cancer since its 
first report, the optimal perioperative IP chemotherapy has not yet been established. Other 
parameters such as volume, novel cytotoxic agents and their dose, are still unexplored. To 
optimize and to gain a complete insight into the IPEC process, all parameters should be 
evaluated. A pharmacokinetic model should be developed which makes it possible to predict 
the outcome of the applied parameters. Afterwards these parameters should be evaluated in 
randomized trials, based on the results of these experimental data and the developed PK/PD 
model. The need to perform more randomized trials has been noted for several years. For the 
moment 3 large, randomized trials are ongoing in the Netherlands, France and Italy. These 
studies will help to answer questions about the role of IPEC following neoadjuvant 
chemotherapy, the efficacy of IPEC and the morbidity typical for IPEC. However these studies 
do not provide answers on the questions concerning the different parameters used during 
IPEC.  
Poor drug penetration into tumor tissue remains an important factor. This penetration issue 
is attributed to the high interstitial fluid pressure caused by vascular hyperpermeability and 
the lack of functional lymphatics [1]. While traditionally chemotherapy is chosen in function 
of the tumor type, a new treatment strategy is that the tumor is adjusted to the 
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chemotherapy. For example, this is possible by using angiogenesis inhibitors (for example 
bevacizumab, Avastin®), which would normalise the vasculature and reduce the interstitial 
fluid pressure. For IV therapy, it is already proven that by pretreatment with angiogenesis 
inhibitors the chemotherapy reaches the tumor in higher concentrations. The same would be 
possible for IP treatment. The promising data emerging from regional administration of 
chemotherapy has prompted interest and investigation into the IP administration of non-
cytotoxic agents with antineoplastic effects. Areas of active investigation include the regional 
instillation of gene vectors, immunotherapy and monoclonal antibodies [2]. 
 
From a pharmaceutical point of view, research should be performed to develop new 
formulations specifically designed for IP treatment as current IP treatment relies on the off-
label use of products developed for IV applications. The main goal for IP drug delivery systems 
is to maintain a high local drug concentration within the peritoneal cavity, whereby drug 
delivery systems which remain in the peritoneal cavity for a longer period and release their 
drug slowly over a prolonged period are the most promising systems. Another major concern 
after cytoreductive surgery (CRS) is the formation of peritoneal adhesions. During the removal 
of the tumor nodules, peritoneal defects are created. These peritoneal defects are the basis 
in the development of peritoneal adhesions. Peritoneal adhesions cause abdominal pain, are 
ideal places for new tumor development and they affect postsurgical IP chemotherapy by 
impeding a uniform drug distribution in the abdominal cavity [3, 4]. Thus, drug delivery 
systems, such as hydrogels, should be developed, which release their drug slowly and also 
prevent the development of peritoneal adhesions after surgery. To evaluate this new 
hydrogels a new animal model should be developed, to evaluate both the anti-tumor effect 
and the prevention against peritoneal adhesions. 
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SUMMARY 
Ovarian cancer is the second most common gynaecological malignancy. As the symptoms of 
ovarian cancer are vague (e.g. abdominal pain, bleeding and abdominal swelling), most 
patients already show dissemination on the peritoneum, called peritoneal carcinomatosis, at 
the time of diagnosis. Advanced stage ovarian cancer remains confined to the peritoneal 
cavity for a prolonged period of time which makes it a good candidate for regional cancer 
treatment. Lately, the new standard of care consists of removing all visible disease by 
extensive surgery, followed by (hyperthermic) intraoperative intraperitoneal chemotherapy 
((H)IPEC). Although IPEC has already been performed for many years in the specialized 
centres, no standardized treatment design has been developed in terms of schedule, 
residence time, drug, or carrier solution. Therefore, the aim of this project was to evaluate 
different parameters such as perfusion temperature, cytotoxic formulation and dose and the 
perfusion time used during IPEC treatment. 
Paclitaxel (PTX), a good candidate for IPEC treatment due to its preferred pharmacokinetic 
profile, is not often used because of the side effects caused by Cremophor®EL, the solubilizer 
used in the commercially available PTX formulation, Taxol®. Therefore, in Chapter 1 a new 
nanocrystalline PTX formulation suitable for HIPEC was developed with Pluronic®F-127 as 
single additive to overcome the systemic side effects. A stable PTX nanocrystalline suspension 
(± 400 nm) was prepared via the wet milling technique (60 hours at 150 rpm) obtaining a 
PTX/Plu F127 nanosuspension (4/1 ratio). In vitro cytotoxicity showed a lower toxicity for 
Pluronic®F-127 compared to Cremophor®EL, but a similar cytotoxicity for the 2 formulations. 
The in vivo toxicity of the PTX nanosuspension after HIPEC treatment was evaluated by 
determining the maximum tolerated dose (MTD) and evaluating the bioavailability. The effect 
on tumor growth was evaluated by Magnetic Resonance Imaging (MRI) at day 7 and 14 after 
HIPEC treatment in rats with peritoneal carcinomatosis of ovarian origin. The MTD of this 
nanosuspension was similar compared to Taxol® (30 mg PTX in 125 ml 0.9% NaCl). The PTX 
plasma levels were monitored for 90 min (i.e. 45 min of HIPEC treatment and 45 min post-
treatment), and showed that during HIPEC treatment the PTX plasma levels were similar for 
both formulations. After treatment the PTX levels were increasing for the nanosuspension-
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treated rats, while the PTX concentration remained constant for the rats treated with Taxol®. 
This effect can be explained by the adhesion of the nanoparticles to the intra-abdominal 
mucosa whereby a prolonged release of PTX was created. This approach overcomes one of 
the limitations of conventional intraperitoneal therapy where drugs are rapidly cleared from 
the peritoneal cavity. In spite of this advantage no significant differences on tumor growth 
were observed between Taxol® and the nanosuspension-treated group. However, the MRI 
data showed a significant reduction of tumor volume after HIPEC treatment with the PTX 
nanosuspension compared to the non-treated group.  
In Chapter 2 the added value of hyperthermia (41.5 °C) in combination with different PTX 
formulations (Taxol®, Abraxane® and Genexol®PM) for intraperitoneal chemotherapy (IPEC) 
was investigated in a human ovarian SKOV-3 xenograft tumor model in rats. IPEC treatment is 
characterized by high local doses resulting in a high efficacy and a low systemic toxicity. 
Therefore, for all treatment modalities both the efficacy and toxicity were evaluated. The 
toxicity of the treatment modalities was evaluated by determining the maximum tolerated 
dose (MTD), recovery time and bioavailability. The efficacy of the different treatment 
protocols was evaluated by a tumor growth delay study (TGD) and by analysing the PTX 
concentration in the tumor. The additional effect on the tumor growth of hyperthermia in 
combination with the PTX formulations was evaluated using a LAPLACE estimation method in 
NONMEM®. The MTD of Genexol®PM (0.27 mg PTX/ml) after HIPEC treatment was higher 
compared to the MTD of Abraxane® and Taxol® (0.24 mg PTX/ml). A faster recovery was 
observed after normothermic treatment with Abraxane® and Genexol®PM compared to 
hyperthermic treatment and treatment with Taxol® (both hyperthermic and normothermic). 
The bioavailability study showed higher PTX plasma concentrations for Abraxane® compared 
to Taxol® and Genexol®PM. No significant differences in bioavailability were observed 
between normothermic and hyperthermic conditions. Compared to the non-treated group 
tumor volume decreased after IPEC treatment for all treatment modalities. Although the PTX 
concentration in the tumor was independent of the formulation or temperature, (H)IPEC 
treatment with Abraxane® showed a higher decrease in tumor volume compared to Taxol® 
and Genexol®PM. This can suggest that the effect of Abraxane® is determined by both the PTX 
tumor penetration and the recirculation of PTX. No significant decrease in tumor volume was 
observed between the different temperatures. Hyperthermia gives no added value to IPEC 
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treatment as a higher toxicity and an equal efficacy was observed compared to normothermic 
treatment.  
The tumor penetration of a cytotoxic drug after IP therapy is a limiting factor for treatment 
efficacy. Limited information is available about the PTX penetration after IP administration. In 
Chapter 3, the penetration profile of PTX into the tumor was examined and the efficacy of this 
penetration was evaluated by scoring the apoptosis. In a second phase, an exploratory study 
was performed in order to characterize the tumor penetration, systemic pharmacokinetics 
(PK) and pharmacodynamics (PD) of PTX after IPEC (by varying the contact time and dose of 
the treatment). In this study, Taxol® was used as PTX formulation. To evaluate the PTX tumor 
concentration and the apoptosis in function of time, a biopsy of the tumor was taken at 
different time points. One half of the biopsy was used for PTX analysis by UPLC-MS, the other 
half was formalin-fixed and paraffin-embedded for the apoptosis study by cleaved caspase-9 
staining. The measured PTX concentrations gradually decreased in function of tumor depth, 
and high PTX concentrations were observed up to 4 mm into the tumor. No differences in PTX 
concentrations were measured between the side of the tumor connected to the abdominal 
wall and the tumor side embedded in the abdominal cavity, meaning that PTX is uniformly 
distributed in the tumor cell layer by cell layer. Similar results were found in the apoptosis 
study as the highest degree of apoptosis was observed in the outer layer of the tumor. Varying 
the contact time or lowering the PTX dose had no influence on the PTX penetration profile. 
The penetration profile was not affected when the treatment time was varied between 5 min 
up to several hours post-treatment. Although the intratumoral PTX concentrations are similar, 
differences in degree of apoptosis were observed. While a high degree of apoptosis (12 ± 4%) 
was observed after IPEC treatment of 45 min with 0.24 mg/ml PTX, only a low amount of 
apoptosis was observed when lowering the contact time (6 ± 1%) or using a dose of 0.024 
mg/ml PTX (4 ± 1%).  
In Chapter 4 the pharmacokinetics of the perfusion temperature, perfusion time and the dose 
were evaluated in a clinical trial using oxaliplatin as cytotoxic agent. 38 patients were treated 
for primary or recurrent peritoneal carcinomatosis with cytoreductive surgery and (H)IPEC. 
The patients were divided in 3 different (H)IPEC treatment groups: 90 min 200 mg/m2 
oxaliplatin treatment at 37 °C (group 1), 30 min 460 mg/m2 oxaliplatin treatment at 37 °C 
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(group 2) and 30 min 460 mg/m2 oxaliplatin treatment at 41 °C (group 3). The amount of 
platinum (Pt) in the perfusate and blood was determined by inductively coupled plasma-mass 
spectrometry (ICP-MS), and platinum tissue penetration was analysed by laser ablation ICP-
MS (LA-ICP-MS). Postoperatively, morbidity and mortality were also evaluated. Comparing the 
normothermic and the hyperthermic-treated groups (group 2 versus group 3) no significant 
differences in pharmacokinetic parameters were observed. Also no differences were observed 
in the Pt tissue penetration profile. Nevertheless, the clinical data showed an increased 
systemic toxicity for patients treated under hyperthermic conditions. Comparing a short high 
dose treatment (group 2) with a long low dose treatment (group 1), both under normothermic 
conditions, showed differences in the pharmacokinetic profile. The Cmax was significantly 
higher for patients in group 2, while the AUCt=7days was similar for both groups resulting in a 
similar systemic toxicity. Also the tissue penetration was much higher for the patients of group 
2 compared to patients of group 1 (24.8 ± 13.2% versus 2.7 ± 2.6%). These data indicated that 
the dose is an important factor for IPEC treatment while the contact time is of less importance.   
In summary, it was clearly shown that hyperthermia had no additional effect on IPEC 
treatment and that the used dose is a more important factor compared to the perfusion time. 
Genexol®PM, Abraxane® and PTX/Plu F127 nanosuspension (4/1 ratio) are suitable 
formulations to replace Taxol® for the treatment of peritoneal carcinomatosis of ovarian 
origin. In this context future research should be focussing on optimizing IPEC therapy by 
evaluating the different parameters and developing of a pharmaceutical formulation which 
releases its cytotoxic agent for a prolonged period. 
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SAMENVATTING 
Ovarium of eierstokkanker is de tweede meest voorkomende gynaecologische kanker bij 
Europese vrouwen. Omdat de symptomen bij eierstokkanker, steeds terugkerende buikpijn, 
licht vaginaal bloedverlies en een opgeblazen gevoel, vaag zijn en pas laattijdig optreden, 
worden bij de meeste patiënten reeds uitzaaiingen op het buikvlies (peritoneale 
metastasering) vastgesteld op het moment van de eerste diagnose. De uitzaaiingen bij 
gevorderde ovariumkanker (stadium III en IV volgens de FIGO richtlijnen) blijven meestal 
beperkt tot de buikholte, verdere uitzaaiingen naar de longen, de lever of andere organen 
komen niet vaak voor. De behandeling van buikvlieskanker bestaat erin de zichtbare kanker 
nodules chirurgisch te verwijderen. Om te voorkomen dat de overblijvende losse en niet-
zichtbare kanker cellen zich opnieuw gaan inplanten en uitbreiden is er de laatste jaren een 
techniek ontwikkeld waarbij de buik tijdens de operatie gespoeld wordt met (verwarmde) 
chemotherapie ((H)IPEC). Hoewel (H)IPEC al sinds eind de jaren ‘90 wordt uitgevoerd in de 
gespecialiseerde centra, bestaat er nog steeds geen algemene behandelingsmethode die de 
behandelingsduur, het gebruik van de verschillende cytotoxische geneesmiddelen en het 
gebruikte vehiculum beschrijft. Tijdens deze studie werden verschillende parameters zoals de 
behandelingstemperatuur, de gebruikte farmaceutische formulatie, de gebruikte dosis en de 
perfusietijd tijdens IPEC geëvalueerd.  
Paclitaxel (PTX) is door zijn goede farmacokinetische eigenschappen een uitstekende 
kandidaat als cytotoxisch geneesmiddel voor (H)IPEC behandelingen. PTX wordt echter niet 
vaak gebruikt omdat Cremophor®EL, het excipiënt aanwezig in het commercieel verkrijgbare 
Taxol®, allergische reacties kan veroorzaken. Om deze nevenwerkingen te voorkomen, werd 
er in Hoofdstuk 1 een nieuwe nanokristallijne PTX formulatie ontwikkeld voor het gebruik bij 
(H)IPEC behandelingen met  
Pluronic®F-127 als enige excipiënt. Via de wet milling techniek, werden PTX en Pluronic®F-127 
60 uur aan 150 tpm gemalen, waardoor een stabiele nanosuspensie (± 400 nm) werd 
verkregen met een PTX/Plu F127 ratio van 4/1. De cytotoxiciteit van Taxol®, de PTX/Plu F127 
nanosuspensie en hun excipiënten werd in vitro getest.  
 Samenvatting 
 
  
136  
 
Hoewel de cytotoxiciteit van Pluronic®F-127 lager was dan deze van Cremophor®EL was de 
cytotoxiciteit van beide formulaties vergelijkbaar door het effect van PTX. Een goede 
formulatie voor (H)IPEC behandelingen wordt gekenmerkt door een hoge lokale 
geneesmiddel concentratie in combinatie met een lage systemische toxiciteit. De toxiciteit van 
de PTX nanosuspensie en Taxol® na een HIPEC behandeling werd geëvalueerd door het 
bepalen van de maximum tolereerbare dosis (MTD) en het evalueren van de biologische 
beschikbaarheid. Het effect van de formulaties werd geëvalueerd door de evolutie van de 
tumorgroei (TGD) via magnetische resonantie (MRI) op te volgen na HIPEC behandeling. Het 
initiële tumorvolume werd bepaald op dag 0, de dag nadien, op dag 1, ondergingen de ratten 
een HIPEC behandeling waarvan het effect aan de hand van het tumorvolume werd bepaald 
op dag 7 en dag 14.  
De MTD was voor beide formulaties (Taxol® en de PTX nanokristallijne formulatie) gelijk aan 
30 mg PTX opgelost in 125 ml 0.9% NaCl. De PTX plasma waarden werden gevolgd over een 
periode van 90 min, concreet wil dit zeggen dat de plasmawaarden werden opgevolgd tijdens 
de 45 min durende HIPEC alsook de eerste 45 min post-operatief. De PTX plasmaconcentraties 
waren tijdens de behandeling voor beide formulaties vergelijkbaar. Na het verwijderen van de 
cytotoxische Taxol®-oplossing bleven de PTX spiegels constant, terwijl de PTX levels in het 
plasma bleven stijgen na de behandeling met de nanokristallijne formulatie. Dit kan verklaard 
worden door het feit dat de nanopartikels zich vasthechten op de mucosa vanwaar ze 
geleidelijk worden vrijgesteld. Op deze manier wordt er een verlengde PTX afgifte verkregen. 
Deze verlengde vrijstelling zorgt ervoor dat één van de limiterende factoren van HIPEC, de 
snelle klaring van het geneesmiddel uit de buikholte via de lymfevaten, wordt overwonnen. 
Ondanks dit grote voordeel werden er geen verschillen tussen beide formulaties 
waargenomen in tumorvolume na de HIPEC behandeling. Wel was er een procentuele daling 
in het tumor volume voor beide formulaties in vergelijking met de niet-behandelde ratten. 
In Hoofdstuk 2 werd de toegevoegde waarde van hyperthermie (41.5 °C) in combinatie met 
verschillende PTX formulaties (Taxol®, Abraxane® en Genexol®PM) voor intraperitoneale 
chemotherapie in een SKOV-3 xenograft rat model geëvalueerd. Het grote voordeel van IPEC 
is dat er hoge dosissen chemotherapie kunnen gebruikt worden waardoor een hoger effect 
(meer celdood) kan bereikt worden maar door de aanwezigheid van de peritoneale-plasma 
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barrière blijft de systemische toxiciteit beperkt. De toxiciteit van de verschillende 
behandelingsgroepen werd geëvalueerd via een MTD studie, het herstel van het 
lichaamsgewicht na IPEC en de PTX plasma concentraties. Het effect van de behandeling werd 
nagegaan aan de hand van de evolutie van de tumorgroei alsook door het bepalen van de 
hoeveelheid gepenetreerde PTX in de tumor. De MTD van Taxol® en Abraxane® na een HIPEC 
behandeling werd vastgelegd op 0.24 mg/ml terwijl voor Genexol®PM een MTD van 0.27 
mg/ml werd bepaald. Het gewicht van de ratten was sneller genormaliseerd na een 
normotherme behandeling (37 °C) met Abraxane® of Genexol®PM terwijl hogere PTX plasma 
spiegels werden vastgesteld voor Abraxane® in vergelijking met Taxol® of Genexol®PM. Er 
werden geen significante verschillen in biologische beschikbaarheid vastgesteld tussen de 
normotherme en de hypertherme behandelingen. Het tumor volume daalde na behandeling 
met alle PTX formulaties in vergelijking met de niet-behandelde groep. Behandeling met 
Abraxane® gaf een grotere daling in tumor volume in vergelijking met een behandeling met 
Genexol®PM en Taxol®. De hogere PTX plasma spiegels na een IPEC behandeling met 
Abraxane® kunnen niet enkel leiden tot een hogere toxiciteit maar zouden er ook voor kunnen 
zorgen dat de hoeveelheid PTX die terugkeert naar de tumor (recirculatie) groter is, waardoor 
dit mechanisme ook inwerkt op de inhibitie van de tumorgroei. Een hypertherme behandeling 
had geen extra invloed op de procentuele daling in tumor volume. In de tumor werden hoge 
PTX concentraties gevonden onafhankelijk van de gebruikte formulaties of temperatuur. Uit 
deze resultaten kan er geconcludeerd worden dat hyperthermie geen toegevoegde waarde 
heeft voor het gebruik bij IPEC behandelingen. Na een HIPEC behandeling is de toxiciteit 
duidelijk hoger terwijl er geen significante verbetering in effect waarneembaar is. Uit deze 
studie blijkt dat zowel Genexol®PM en Abraxane® goede formulaties zijn om Taxol® te 
vervangen bij IPEC behandelingen. 
Uit verschillende studies blijkt dat de penetratie van het cytotoxisch geneesmiddel in de tumor 
na een IP behandeling de limiterende factor is. Over de penetratie van PTX in de tumor 
bestaan er nog heel wat onduidelijkheden. Daarom werd in Hoofdstuk 3 het penetratieprofiel 
van PTX opgesteld. Het effect van de PTX penetratie werd geëvalueerd door het scoren van 
de apoptose. In een tweede fase werd een preliminaire studie uitgevoerd waarbij aan de hand 
van de tumorpenetratie de farmacokinetiek (PK) en de farmacodynamiek (PD) van PTX na IPEC 
werd geanalyseerd. Dit gebeurde door de behandelingsduur en de toegediende dosis te 
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variëren. In de volledige studie werd Taxol® gebruikt als PTX formulatie. Om de evolutie van 
de PTX concentratie en de hoeveelheid apoptose in de tumor te evalueren in functie van de 
tijd, werd er een biopsie van de tumor genomen op verschillende tijdpunten bij verschillende 
ratten. Deze cilinder werd verdeeld in twee helften, de ene helft werd diepgevroren, hiervan 
werd de PTX concentratie bepaald door UPLC-MS, de andere helft werd gefixeerd in formol 
en daarna ingebed in paraffine. Deze geparaffineerde coupes werden gebruikt voor de 
apoptose studie. De geobserveerde PTX concentraties in de tumor daalden gradueel in functie 
van de diepte. Concreet werden er hoge PTX concentraties gevonden tot 4 mm diepte. De 
oriëntatie van de tumor in de buikholte speelde geen rol, de concentraties die gevonden 
werden aan de zijde van de tumor die in rechtstreeks contact stond met de cytotoxische 
oplossing zijn even groot als de concentraties gevonden aan de zijde die verbonden was met 
de buikspier. Dit toont aan dat PTX per cellaag homogeen verdeeld is in de volledige tumor. 
De apoptose studie bevestigt deze resultaten. De graad van apoptose was veel hoger in de 
buitenste (cel)lagen van de tumor en meer naar het centrum van de tumor daalde de 
apoptose. Een kortere behandelingsduur of het toedienen van een lagere dosis PTX had geen 
invloed op de hoeveelheid PTX die penetreerde in de tumor. Hoewel de intra-tumorale 
concentraties niet varieerden, waren er wel duidelijke verschillen in graad van apoptose 
zichtbaar bij het variëren van de perfusietijd of PTX dosis. Bij de standaard behandeling 
(0.24 mg/ml PTX en een perfusietijd van 45 min) was er 12 ± 4% van de cellen in apoptose, 
terwijl na een korte behandeling van 15 min slechts 6 ± 1% van de cellen apoptotisch waren. 
Het verlagen van de dosis tot 0.024 mg/ml leverde een apoptose van 4 ± 1% op.  
In Hoofdstuk 4 werd tijdens een klinische studie het effect van de perfusie temperatuur, de 
perfusietijd en de gebruikte dosis op de farmacokinetiek van oxaliplatine nagegaan. In deze 
studie werden 38 patiënten met peritoneale uitzaaiingen van verschillende primaire 
oorsprong behandeld met een cytoreductive chirurgie gevolgd door een intraperitoneale 
spoeling (H)IPEC met oxaliplatine. Deze patiënten werden verdeeld in 3 verschillende (H)IPEC 
groepen. Groep 1 zijn de patiënten die 90 min behandeld werden met 200 mg/m2 oxaliplatine 
bij 37 °C, groep 2 bevat de patiënten die een 30 min durende behandeling kregen met 460 
mg/m2 oxaliplatine bij 37 °C en in groep 3 werden patiënten 30 min behandeld met 460 mg/m2 
oxaliplatine onder hypertherme omstandigheden (41 °C). Tijdens en na de (H)IPEC 
behandeling werden er perfusaat-, bloed- en weefselstalen genomen. In deze bloed- en 
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perfusaatstalen werd de hoeveelheid platinum bepaald door inductively coupled plasma-mass 
spectrometry (ICP-MS) en de platinum concentratie in de weefselstalen werd geanalyseerd 
door laser ablation ICP-MS (LA-ICP-MS). Postoperatief werd ook de mortaliteit en de 
morbiditeit geëvalueerd. Het vergelijken van de farmacokinetische parameters bij de 
normotherme en hypertherme behandelde patiënten (groep 2 vs. Groep 3) leverde geen 
significante verschillen op. Ook de platinum weefselpenetratie was voor beide groepen 
vergelijkbaar. Ondanks deze gelijklopende platinum concentraties vertoonden de klinische 
gegevens wel een verhoogde toxiciteit voor de patiënten behandeld bij 41 °C. In een tweede 
deel van de studie werd een korte behandeling met een hoge dosis oxaliplatine (groep 2) 
vergeleken met een lange behandeling met een lage dosis oxaliplatine (groep 1), bij beide 
groepen was de temperatuur identiek (37 °C). Bij de patiënten in groep 2 werd er een hogere 
maximale platinum concentratie waargenomen. Deze concentratie daalde echter zeer snel 
waardoor de AUCt=7dagen voor beide behandelingsstrategieën hetzelfde was. Daardoor werden 
er ook geen verschillen gevonden in de toxiciteit tussen beide groepen. De weefselpenetratie 
was significant hoger voor patiënten uit groep 2 in vergelijking met patiënten uit groep 1 (24.8 
± 13.2% vs. 2.7 ± 2.6%). Doordat de platinum weefsel concentratie veel hoger was voor de 
groep patiënten behandeld met een hoge dosis platinum terwijl dit niet resulteerde in een 
hogere toxiciteit, kan er geconcludeerd worden dat de dosis een groter effect zal hebben op 
de farmacokinetiek dan de perfusietijd. 
De algemene conclusie aan het einde van dit onderzoek is dat hyperthermie geen 
toegevoegde waarde heeft voor de IPEC behandeling van patiënten met uitzaaiingen op het 
buikvlies. De dosis die gebruikt wordt tijdens de IPEC behandeling lijkt van cruciaal belang 
terwijl de perfusietijd eerder minder invloed lijkt te hebben. Alle geëvalueerde formulaties, 
Abraxane®, Genexol®PM en PTX/Plu F127, kunnen gebruikt worden voor IPEC behandelingen 
en zijn goede alternatieven voor Taxol®. Echter zal er in de toekomst nog verder onderzoek 
moeten gevoerd worden om IPEC behandelingen verder te optimaliseren. Ook dient er 
nagegaan te worden of er geen formulatie kan ontwikkelend worden specifiek voor 
intraperitoneale toepassingen. Een formulatie die een lange tijd in de buikholte kan verblijven 
terwijl ze continu hoge dosissen aan cytotoxisch geneesmiddel vrijstelt, lijkt het meest 
beloftevolle alternatief voor IPEC behandelingen. 
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